Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 PRIVILEGED AND
CONFIDENTIAL 
 Morgan Stanley Senior Funding, Inc. 

1585 Broadway 
 New York, New York
10036 
 June 2, 2014 

Endurance Specialty Holdings Ltd. 
 Wellesley House 

90 Pitts Bay Road 
 Pembroke, HM 08 

Bermuda 
 Attention:  Michael J. McGuire, Chief
Financial Officer 
 Ladies and Gentlemen: 

Project Sail 
 $1,000,000,000
Facility 
 Commitment Letter 

You (“you” or the “Borrower”) have advised Morgan Stanley Senior Funding, Inc. (“MSSF”, and
together with each assignee permitted by the terms of this Commitment Letter that becomes a party to this Commitment Letter as an additional “Commitment Party” pursuant to Section 2 hereof, collectively, the “Commitment
Parties”, “we” or “us”) that you intend to acquire all of the ordinary shares (the “Acquisition”) of Aspen Insurance Holdings Limited (the “Target”, and together with its
subsidiaries, the “Target Business”). The Acquisition will be effected through one of (a) a two-step transaction pursuant to which the Borrower or a newly formed wholly-owned subsidiary of the Borrower (“Merger
Sub”) makes an exchange offer (the “Offer”) to acquire all of the ordinary shares of the Target, par value 0.15144558 ¢ per share (together with the associated preferred stock purchase rights) (the “Target
Shares”) for a combination of cash and equity interests in the Borrower as more fully described in the Offer Documents (as defined in the Term Sheet (as defined below)), followed as promptly as practicable after the consummation of the
Offer by a merger of the Target with the Borrower or Merger Sub, with the Borrower surviving such merger or Merger Sub or Target surviving such merger as a wholly owned subsidiary of the Borrower (the “Second-Step Merger”) or the
acquisition of all the Target Shares not acquired in the Offer pursuant to Section 102 or 103 of the Bermuda Companies Act 1981 (a “Compulsory Acquisition”) (the Second-Step Merger or a Compulsory Acquisition, together with the
Offer, the “Two-Step Acquisition”), (b) a single-step merger (the “One-Step Merger”) pursuant to an agreement and plan of merger (a “Merger Agreement”), pursuant to which the Target will be
merged with the Borrower or Merger Sub, with the Borrower surviving such merger or Merger Sub or the Target 

 
surviving as a wholly owned subsidiary of the Borrower or (c) a court-sanctioned scheme of arrangement under Bermuda law pursuant to which Borrower acquires all of the Target Shares (the
“Scheme”).1 References herein to (i) the “Merger” shall mean the merger of the Target with the Borrower or Merger Sub, with the Borrower surviving such merger or
Merger Sub or Target surviving such merger as a wholly owned subsidiary of the Borrower, whether pursuant to a Second-Step Merger or a One-Step Merger, and (ii) the “Acquisition” shall include the Acquisition whether consummated
pursuant to a Two-Step Acquisition, a One-Step Merger or the Scheme. 
 In that connection, you have advised us that the total amount
required to effect the Acquisition (excluding common shares of the Borrower issued as direct consideration therefor) and to pay the fees and expenses incurred in connection therewith shall be provided by a combination of (a) cash on the balance
sheet, (b) the issuance by the Borrower of a combination of equity securities, equity-linked securities and unsecured debt securities (the foregoing, collectively, the “Securities”), and/or (c) to the extent the Borrower
does not issue the Securities on or prior to the Closing Date (as defined below), the borrowing by the Borrower of loans under a 364-day senior unsecured bridge term loan facility (the “Facility”) in an aggregate principal amount
not to exceed $1,000,000,000. The Acquisition, the Facility and the transactions contemplated by or related to the foregoing are collectively referred to as the “Transactions”. No other financing will be required for the
Transactions. 
 The date on which (i) in the case of a Two-Step Acquisition, shares are first accepted for payment under the Offer,
(ii) in the case of a One-Step Merger, the Merger is consummated and (iii) in the case of a Scheme, the effective date of the Scheme under Bermuda law is herein referred to as the “Closing Date”. The date on which the
Facility is funded is hereinafter referred to as the “Funding Date”. 
 1. Commitment. MSSF is pleased to
commit to provide 100% of the aggregate principal amount of the Facility, subject to and on the terms and conditions set forth in this letter and in the Summary of Terms and Conditions attached hereto as Exhibit A (including the Annex attached
thereto) and the Conditions Precedent to Closing attached hereto as Exhibit B (collectively, the “Term Sheet” and collectively with this letter, this “Commitment Letter”); provided that, the amount of the
Facility and the aggregate commitment of the Commitment Parties hereunder for the Facility shall be automatically reduced at any time on or after the date hereof as set forth in the section titled “Mandatory Prepayments” in Exhibit A
hereto. It is understood that MSSF shall act as sole lead arranger and sole bookrunner (in such capacity, the “Arranger”) and sole administrative agent for the Facility. You agree that, as a condition to the commitments, agreements
and undertakings set forth herein, no other agents, co-agents, arrangers or bookrunners will be appointed, no other titles will be awarded and no compensation will be paid in connection with the Facility, unless you and we shall agree. It is further
agreed MSSF will have “upper left” placement in all documentation used in connection with the Facility and shall have all roles and responsibilities customarily associated with such placement. 

Our obligation to fund our commitment hereunder is subject solely to the following: 

(A) the negotiation, execution and delivery on or before the Commitment Termination Date (as defined below) of definitive documentation for
the Facility consistent with the terms set forth in this Commitment Letter and otherwise reasonably satisfactory to us and you (the “Credit 

 

	1 	 For purposes of this Commitment Letter, “wholly-owned subsidiary” means ownership of all of the ordinary shares or other common equity
interests of the subsidiary. 

  
 2 

 
Documentation”). The “Commitment Termination Date” shall be (i) December 31, 2014 if the Merger Agreement is not executed prior to December 31, 2014,
or (ii) if the Merger Agreement is executed on or prior to December 31, 2014, the earliest to occur of (x) the termination date specified in the Merger Agreement, (y) 6 months from the date of the execution of the Merger
Agreement plus up to an additional 3 months to obtain regulatory approvals to the extent deemed advisable by the Borrower to effect the Transactions (and to the extent the termination date under the Merger Agreement is similarly extended, if
necessary) and (z) 15 months from the date hereof; and 
 (B) the other conditions set forth or referred to in Exhibit B. 

Notwithstanding anything to the contrary contained in this Commitment Letter or the Fee Letter or any other letter agreement or undertaking
concerning the financing of the Acquisition, the only conditions to closing and funding of our commitment hereunder on the Closing Date shall be those expressly set forth in this Section 1 and in Exhibit B, and upon satisfaction (or waiver) of
such conditions, the initial funding of the Facility shall occur; it being understood that there are no conditions (implied or otherwise) to the commitments hereunder, including compliance with the terms of this Commitment Letter, the Fee Letter and
the Credit Documentation, other than those that are expressly stated herein to be conditions to the initial funding of the Facility on the Closing Date. Notwithstanding anything in this Commitment Letter, the Fee Letter or the Credit Documentation
or any other letter agreement or other undertaking concerning the financing of the transactions contemplated herein to the contrary, (a) neither the making nor the accuracy of any representations or warranties relating to the Target Business
(and their businesses) shall be a condition to the availability of the Facility on the Closing Date (except to the extent of any such representations and warranties that are included in the Merger Agreement Representations (as defined below)),
(b) if a Merger Agreement is entered into, the only representations relating to the Target Business and their businesses the accuracy of which shall be a condition to availability of the Facility on the Closing Date shall be such of the
representations made by or on behalf of the Target Business in such Merger Agreement, if any, as are material to the interests of the Lenders, but only to the extent you have (or your applicable affiliate has) the right to terminate your (or its)
obligations under the Merger Agreement (or the right to not consummate the Acquisition) as a result of a breach of such representations in the Merger Agreement (the “Merger Agreement Representations”), (c) the only
representations relating to the Borrower and its subsidiaries and their respective businesses the accuracy of which shall be a condition to availability of the Facility on the Closing Date shall be the Specified Representations (as defined in
Exhibit B hereto), and (d) to the extent applicable, the terms of the Credit Documentation shall be in a form such that they do not impair availability of the Facility on the Closing Date if the conditions expressly set forth in this Commitment
Letter are satisfied. 
 Notwithstanding anything to the contrary contained in this Commitment Letter or the Fee Letter or any other letter
agreement or undertaking concerning the financing of the Acquisition, from and after the date of the execution and delivery of the Credit Documentation, the only consent that will be required to waive the conditions precedent to the initial funding
of the Facility on the Closing Date is the consent of the Lenders holding a majority of the Commitments outstanding at such time. 
 Without
limiting the conditions precedent expressly provided herein to funding the consummation of the Acquisition with the proceeds of the Facility, the Arranger will cooperate with you as reasonably requested in coordinating the timing and procedures for
the funding of the Facility in a manner consistent with this Commitment Letter. 
 2. Syndication. The Arranger reserves the
right, prior to or after execution of the Credit Documentation, in consultation with you, to syndicate all or a part of our commitment to the Facility to one or more Lenders (as defined in the Term Sheet), which syndication shall be managed by the
Arranger in consultation with the Borrower; provided that we agree that, prior to the funding of the Facility, we will not sell, assign, participate or otherwise transfer or dispose of our commitment to the Facility to the extent

  
 3 

 
that, after giving effect to such sale, assignment, participation, transfer or disposition, we (and our affiliates subject to Section 9 hereof) and two other Lenders that are set forth on a
list that you and we have agreed to in writing on or prior to the date hereof would hold less than 50.1% of the aggregate commitments in respect of the Facility. Notwithstanding anything to the contrary herein, until the earlier of a Successful
Syndication (as defined in the Fee Letter referred to below) and the date that is 30 days after the date hereof, potential Lenders shall be limited to persons (i) that are lenders under the Existing Credit Agreement (as defined in the Term
Sheet) as of the date hereof and (ii) that you and we have agreed to in writing on or prior to the date hereof (each of the persons described in clauses (i) and (ii), a “Permitted Assignee”). From the date that is 31 days
after the date hereof to and including the Funding Date, the Arranger may syndicate the facility to Permitted Assignees and, with your consent (which consent may or may not be provided in your sole discretion), to other potential Lenders. After the
Funding Date, the Arranger may syndicate the Facility to Permitted Assignees and, with your consent (not to be unreasonably withheld) and subject to the “Assignment” provisions of the Term Sheet, other potential Lenders. The commitment of
MSSF hereunder with respect to the Facility shall be reduced dollar-for-dollar as and when commitments for the Facility are received from Lenders to the extent that each such Lender becomes (i) party to this Commitment Letter as an additional
“Commitment Party” pursuant to a joinder agreement or other documentation, in each case reasonably satisfactory to the Arranger and you or (ii) party to the applicable Credit Documentation as a “Lender” thereunder subject to
the terms of this Section 2. The Arranger intends to commence syndication efforts as soon as is practicable after the execution of this Commitment Letter by the parties hereto after the Offer has been publicly announced by you, and you agree to
use your commercially reasonable efforts to actively assist the Arranger in completing a syndication reasonably satisfactory to the Arranger and you as soon thereafter as practicable. Subject to the provisions set forth above in this Section 2,
such assistance shall include, without limitation, (a) your using commercially reasonable efforts to ensure that the Arranger’s syndication efforts benefit from your existing lending and investment banking relationships, (b) direct
contact between appropriate senior management and advisors of the Borrower, on the one hand, and the proposed Lenders, on the other hand at reasonable times and intervals to be mutually agreed, (c) your assistance in the preparation of a
Confidential Information Memorandum and other customary marketing materials (other than materials the disclosure of which would violate a confidentiality agreement or waive attorney-client privilege) to be used in connection with the syndication of
the Facility and (d) the hosting, with the Arranger, of a reasonable number of meetings or conference calls with prospective Lenders, at times, intervals and locations to be mutually agreed upon, as deemed reasonably necessary by the Arranger.
Until the earlier of the achievement of a Successful Syndication and the date that is 60 days after the Funding Date (such earlier date, the “Syndication Date”), you agree, unless consented to by MSSF, that there shall be no
competing offering, placement or arrangement of any commercial bank or other credit facilities by or on behalf of the Borrower or any of its subsidiaries that could reasonably be expected to impair the primary syndication of the Facility in any
material respect, other than Excluded Debt (as defined in the Term Sheet) (provided that you will reasonably coordinate with us in connection with any refinancing or replacement of the Existing Credit Agreement (as defined in the Term Sheet),
including by copying us on all material documents and communications and consulting with us as to timing, selection of lenders, awarding of titles and timing and content of material communications to the lenders as a group). Subject to the
applicable provisions above, the Arranger will manage all aspects of the syndication in active consultation with you, including, without limitation, decisions as to the selection of institutions to be approached and when they will be approached,
when their commitments will be accepted, which institutions will participate (subject to your consent rights as set forth above) and the allocations of the commitments among the Lenders and the amount and distribution of fees among the Lenders. In
acting as the Arranger, MSSF will have no responsibility other than to arrange the syndication as set forth herein and shall in no event be subject to any fiduciary or other implied duties. To assist the Arranger in its syndication efforts, you
agree promptly to prepare and provide to us all information (including, without limitation, using commercially reasonable efforts to provide any consultants’ reports commissioned by you and access to such consultants) with respect to the
Borrower and its subsidiaries and the Transactions, including, without limitation, all financial information and 

  
 4 

 
projections, as the Arranger may reasonably request in connection with the arrangement and syndication of the Facility (it being understood that the projections previously furnished by you to us
have satisfied this request), but excluding any such information the disclosure of which would result in the loss of attorney-client privilege or violate a third-party confidentiality obligation binding upon the Borrower or its subsidiaries;
provided that in the event that you do not provide information in reliance on this sentence, you shall provide notice to the Arranger that such information is being withheld and you shall use your commercially reasonable efforts to obtain a
waiver of such confidentiality obligation and/or communicate, to the extent feasible, the applicable information in a way that would not violate the applicable obligation or risk waiver of such privilege. Without limiting your obligations to assist
with syndication efforts as set forth above, the Commitment Parties agree that none of the commencement of the syndication by the Arranger, the completion of syndication (including a Successful Syndication (as defined in the Fee Letter)) or the
delivery of the information and documents referred to in the last paragraph of this Section 2 is a condition to the initial funding under the Facility. You further agree that, if you and Target (or your or its respective subsidiaries) enter
into a Merger Agreement prior to or in lieu of the consummation of an Offer (a “Negotiated Transaction”), you will thereafter use your commercially reasonable efforts to cause the Target, its senior management, representatives and
advisors to assist in the foregoing matters. 
 You agree that the Arranger may make available any Information (as defined below) and
projections (collectively, the “Company Materials”) to potential Lenders by posting the Company Materials on IntraLinks, the Internet or another similar electronic system (the “Platform”). You further agree to
assist, at the reasonable request of the Arranger, in the preparation of a version of a confidential information memorandum and other marketing materials and presentations to be used in connection with the syndication of the Facility, consisting
exclusively of information or documentation that is either (a) publicly available (or contained in the prospectus or other offering memorandum for any securities to be issued by the Borrower in connection with the Transactions) or (b) not
material with respect to the Borrower, the Target, or their respective subsidiaries or any of their respective securities for purposes of foreign, United States federal and state securities laws (all such information and documentation being
“Public Lender Information”). Any information and documentation that is not Public Lender Information is referred to herein as “Private Lender Information.” You further agree, at our request, to identify any
document to be disseminated by the Arranger to any Lender or potential Lender in connection with the syndication of the Facility as either (i) containing Private Lender Information or (ii) containing solely Public Lender Information
(provided that the Borrower has been afforded an opportunity to comply with the applicable United States Securities and Exchange Commission (“SEC”) disclosure obligations). You acknowledge and agree that the following documents will
contain solely Public Lender Information (except to the extent you notify us to the contrary and provided that you shall have been given a reasonable opportunity to review such documents and comply with applicable SEC disclosure obligations):
(i) drafts and final Credit Documentation; (ii) administrative materials prepared by the Arranger for potential Lenders (e.g., a lender meeting invitation, allocations and/or funding and closing memoranda); and (iii) notification of
changes in the terms of the Facility. 
 3. Information. You hereby represent and warrant (with respect to information
relating to the Target Business, to the best of your knowledge) that (a) all written information (other than projections and other forward looking information (the “Projections”) and information of a general economic or
industry-specific nature) (the “Information”) that has been or will be made available to us or any of our affiliates or any Lender or potential Lender by you, the Target Business, or any of your or its representatives in connection
with the Transactions is or will be, when taken as a whole and when furnished, complete and correct in all material respects and does not or will not, when taken as a whole and when furnished, contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements contained therein not materially misleading in light of the circumstances under which such statements are made (giving effect to all supplements thereto from time to time) and
(b) the Projections that have been or will be made available to us or any of our affiliates or 

  
 5 

 
any Lender or potential Lender by you or any of your representatives in connection with the Transactions have been or will be prepared in good faith based upon assumptions believed by you to be
reasonable at the time furnished (it being understood that such Projections are subject to significant uncertainties and contingencies, any of which are beyond your control, and that no assurance can be given that any particular Projection will be
realized and that actual results may differ and such differences may be material). You agree to supplement the Information and Projections from time to time until the later of (x) the Funding Date and (y) the Syndication Date so that the
representations and warranties in the immediately preceding sentence remain correct. You acknowledge that we will be entitled to use and rely on the Information and Projections without independent verification thereof. 

We reserve the right to employ the services of one or more of our affiliates in providing services contemplated by this Commitment Letter and
to allocate, in whole or in part, to such affiliates certain fees payable to us in such manner as we and our affiliates may agree. You acknowledge that we may share with any of our affiliates, and such affiliates may share with us, any information
related to the Transactions, you and your subsidiaries or the Target Business or any of the matters contemplated hereby in connection with the Transactions. 

4. Fees. As consideration for our commitment hereunder and the Arranger’s agreement to perform the services described
herein, you agree to pay the non-refundable fees (when due and payable) set forth in the Term Sheet and in the Fee Letter delivered herewith from MSSF to you relating to the Facility and dated the date hereof (the “Fee Letter”).

 5. Indemnity and Expenses; Other Activities. You agree (a) to indemnify and hold harmless each Commitment Party and
its affiliates and each officer, director, employee, advisor and agent of each Commitment Party or its affiliates (each, an “indemnified person”) from and against any and all losses, claims, damages and liabilities to which any such
indemnified person may become subject arising out of or in connection with this Commitment Letter, the Fee Letter, the Facility, the use of the proceeds thereof, the Transactions or any related transaction or any claim, litigation, investigation or
proceeding relating to any of the foregoing, regardless of whether any indemnified person is a party thereto and regardless of whether brought by a third party or by the Borrower or any of its affiliates (any of the foregoing, a
“Proceeding”), and to reimburse each indemnified person within 30 days of written demand for any reasonable and documented out-of-pocket expenses incurred in connection with investigating or defending any such Proceeding, including,
the reasonable fees and expenses of one outside counsel to all such indemnified persons taken as a whole, if reasonably required one local counsel to all such indemnified parties as necessary in each appropriate jurisdiction and, solely in the case
of a conflict of interest, one additional counsel to the affected indemnified persons taken as a whole, in each applicable jurisdiction, provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims,
damages, liabilities or related expenses (A) to the extent and for so long as they have been found by a final judgment of the highest court of competent jurisdiction to have considered such matter to arise from (i) the willful misconduct,
bad faith or gross negligence of such indemnified person or its affiliates or (ii) the material breach of this Commitment Letter or the Credit Documentation by such indemnified person or its affiliates or (B) to the extent they arise from
any dispute solely among indemnified persons and not arising out of any act or omission of the Borrower, the Target Business or any of your or its affiliates (other than any such Proceeding against a Commitment Party in its capacity as an Arranger,
Administrative Agent or other similar role) and (b) to reimburse each Commitment Party within 30 days (or, in the case of reimbursement on the Funding Date pursuant to paragraph 7 of Exhibit B, three business days) following written demand
(together with back-up documentation supporting each reimbursement request) for all reasonable out-of-pocket expenses (including, without limitation, reasonable and documented fees, charges and disbursements of one outside counsel to all of the
Commitment Parties, taken as a whole, if reasonably required one local counsel as necessary in each appropriate jurisdiction and, solely in the case of a conflict of interest, one additional counsel to the affected persons taken as a whole in each
applicable jurisdiction) incurred in connection with the Facility 

  
 6 

 
and any related documentation (including, without limitation, this Commitment Letter, the Fee Letter and the Credit Documentation) or the administration, amendment, modification or waiver
thereof. No indemnified person shall be liable for any damages arising from the use by unintended recipients of Information or other materials obtained through electronic, telecommunications or other information transmission systems except to the
extent and for so long as found by a final judgment of the highest court of competent jurisdiction to have considered such matter to arise from the willful misconduct, bad faith or gross negligence of such person. None of you, your subsidiaries,
Target or its subsidiaries or any indemnified person shall be liable for any special, indirect, consequential or punitive damages in connection with the Commitment Letter, the Fee Letter, the Facility, the use of the proceeds thereof, the
Transactions or any related transaction; provided that this sentence shall not limit your indemnification obligations, if any, pursuant to this paragraph to the extent such special, indirect, consequential or punitive damages are included in
any third party claim. 
 You will not, without the prior written consent, not to be unreasonably conditioned, withheld or delayed, of the
indemnified person, settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any Proceeding in respect of which indemnification may be sought hereunder (whether or not any indemnified person is a party thereto)
unless such settlement, compromise, consent or termination (i) includes an unconditional release of each indemnified person from all liability arising out of such Proceeding and (ii) does not include a statement as to, or an admission of,
fault, culpability, or a failure to act by or on behalf of such indemnified person. 
 You acknowledge that each Commitment Party and its
affiliates (the term “Commitment Party” as used below in this paragraph being understood to include such affiliates) may be providing debt financing, equity capital or other services (including, without limitation, financial
advisory services) to other companies in respect of which you may have conflicting interests or a commercial or competitive relationship with and otherwise (except as otherwise agreed in writing by you and us (or our respective affiliates) in
connection with the Transactions). In particular, you acknowledge that Morgan Stanley & Co. LLC (“MS&Co.”) is acting as a buy-side financial advisor to you in connection with the Transactions. You agree not to assert or
allege any claim based on actual or potential conflict of interest arising or resulting from, on the one hand, the engagement of MS&Co. in such capacity and our obligations hereunder, on the other hand. No Commitment Party will use confidential
information obtained from you by virtue of the transactions contemplated hereby or other relationships with you in connection with the performance by the Commitment Parties of services for other companies, and no Commitment Party will furnish any
such information to other companies or their advisors. You also acknowledge that no Commitment Party has any obligation to use in connection with the transactions contemplated hereby, or to furnish to you, confidential information obtained from
other companies. You acknowledge that each Commitment Party is acting hereunder pursuant to a contractual relationship on an arm’s length basis, and the parties hereto do not intend that any Commitment Party in its capacity as such or its
affiliates act or be responsible as a fiduciary to the Borrower, its management, shareholders, creditors or any other person in each case in connection with the financing transactions contemplated hereby. The Borrower hereby expressly disclaims any
fiduciary relationship and agrees that it is responsible for making its own independent judgments with respect to the financing transactions contemplated hereby. The Borrower also acknowledges that no Commitment Party has advised and none is
advising the Borrower as to any legal, accounting, regulatory or tax matters, and that the Borrower is consulting its own advisors concerning such matters to the extent it deems appropriate. 

6. Governing Law, etc. This Commitment Letter shall be governed by, and construed in accordance with, the laws of the State of
New York; provided, however, that the interpretation of the definition of “Combined Material Adverse Effect”, for purposes of this Commitment Letter, shall be governed by, and construed in accordance with, the laws of
the State of Delaware; provided further, however, that, if a Merger Agreement is entered into and pursuant to such Merger Agreement the laws of a jurisdiction other than the State of Delaware would govern the interpretation of
any definition therein of 

  
 7 

 
“Material Adverse Effect” or of any similar term, then the law of such jurisdiction shall govern the interpretation of the definitions of “Combined Material Adverse
Effect” and “Merger Agreement Representations” for purposes of this Commitment Letter to the extent satisfactory to the Arranger at or prior to the time such Merger Agreement is executed (it being understood that the laws
of Bermuda and the laws of the State of New York are satisfactory to the Arranger). The parties hereto hereby waive any right they may have to a trial by jury with respect to any claim, action, suit or proceeding arising out of or contemplated by
this Commitment Letter. The parties hereto submit to the exclusive jurisdiction of the federal and New York State courts located in the County of New York in connection with any dispute related to, contemplated by, or arising out of this Commitment
Letter and agree that any service of process, summons, notice or document by registered mail addressed to such party shall be effective service of process for any suit, action or proceeding relating to any such dispute. The parties hereto
irrevocably and unconditionally waive any objection to the laying of venue of any such suit, action or proceeding brought in any such court and agree that any final judgment in any such suit, action or proceeding brought in any such court shall be
conclusive and may be enforced in other jurisdictions by suit upon the judgment or in any other manner provided by law. If, for the purposes of obtaining a final, nonappealable judgment of a court of competent jurisdiction it is necessary to convert
a sum due hereunder or under the Fee Letter in dollars into another currency, the parties hereto agree, to the fullest extent that they may effectively do so, that the rate of exchange used shall be that at which in accordance with normal banking
procedures, the party entitled to such payment could purchase (and remit in the City of New York) dollars with such other currency on the business day preceding that on which such final, nonappealable judgment of a court of competent jurisdiction is
given. Your obligation in respect of any sum due hereunder or under the Fee Letter shall, notwithstanding any judgment in a currency other than dollars, be discharged only to the extent that on the business day following its receipt of any sum
adjudged to be so due in such other currency, the party entitled to such payment may, in accordance with normal banking procedures, purchase (and remit in the City of New York) dollars with such other currency; if the dollars so purchased and
remitted are less than the sum originally due to the party entitled to such payment in dollars, you agree, as a separate obligation and notwithstanding any such judgment, to indemnify the relevant payee against such loss, and if the dollars so
purchased exceed the sum originally due in dollars, such excess shall be remitted to you. 
 7. PATRIOT Act. We hereby notify
you that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (October 26, 2001), as amended) (the “PATRIOT Act”), the Commitment Parties and the other Lenders may be required to obtain,
verify and record information that identifies you, which information includes your name and address, and other information that will allow the Commitment Parties and the other Lenders to identify you in accordance with the PATRIOT Act. This notice
is given in accordance with the requirements of the PATRIOT Act and is effective for each Commitment Party and the other Lenders. 
 8.
Confidentiality. This Commitment Letter is delivered to you on the understanding that neither this Commitment Letter nor the Fee Letter nor any of their terms or substance shall be disclosed, directly or indirectly, to any other person
except (a) to your officers, directors, employees, shareholders, partners, members, accountants, attorneys, agents and advisors who are directly involved in the consideration of this matter on a confidential and need-to-know basis, (b) as
may be compelled in a judicial or administrative proceeding or as otherwise required by law or requested by a governmental authority (in which case you agree to the extent permitted under applicable law to inform us promptly thereof), (c) in
connection with the exercise of any remedies hereunder or any suit, action or proceeding relating to this Commitment Letter, the Fee Letter or other agreement contemplated thereby or enforcement hereof or thereof, (d) this Commitment Letter
(but not the Fee Letter) may be disclosed to the Target and its officers, directors, employees, accountants, attorneys, agents and advisors who are directly involved in the consideration of this matter on a confidential and need-to-know basis, or
(e) after your acceptance of this Commitment Letter and the Fee Letter, you may disclose this Commitment Letter (but not the Fee Letter) in filings with the SEC and other applicable regulatory authorities and stock

  
 8 

 
exchanges, as required by law, including in any registration statement, proxy statement or other public filing related to the Transactions and (y) with respect to the Term Sheet only, on a
confidential basis to any rating agency in connection with the Transactions and, in consultation with the Arranger, to bona fide prospective Lenders, and (ii) the aggregate amount of fees contained in the Fee Letter, in active consultation with
the Arranger, in any marketing materials or offering memorandum as part of projections, pro forma calculations or a generic disclosure of sources and uses to the extent customary and required and (f) if we consent in writing to such proposed
disclosure. 
 Each Commitment Party will treat as confidential all information provided to it by or on behalf of the Borrower hereunder;
provided that nothing herein shall prevent such person from disclosing any such information (i) to any Lenders or participants or prospective Lenders or participants and any direct or indirect contractual counterparties to any swap or
derivative transaction relating to the Borrower or its obligations under the Facility (collectively, “Specified Counterparties”), (ii) to its officers, directors, employees, shareholders, partners, members, accountants,
attorneys, agents, advisors and to actual or prospective assignees and participants on a confidential basis, (iii) as may be compelled in judicial or administrative proceeding or as otherwise required by law or requested by a governmental
authority (in which case such person agrees to the extent permitted under applicable law to inform you promptly thereof), (iv) to any rating agency in connection with the Transactions on a confidential basis, (v) as requested by any state,
federal or foreign authority or examiner regulating banks or banking (in which case we shall, except with respect to any audit or examination conducted by bank accountants or any governmental bank regulatory authority exercising examination or
regulatory authority, to the extent permitted under applicable law, inform you promptly thereof), (vi) in connection with the exercise of any remedies hereunder or any suit, action or proceeding relating to this Commitment Letter, the Fee
Letter, or the transaction contemplated thereby or enforcement hereof and thereof, (vii) to any of its affiliates on a confidential and need to know basis and (viii) to the extent such confidential information becomes publicly available
(x) other than as a result of a breach of this provision or (y) to it from a source, other than the Borrower, which it has no reason to believe has any confidentiality or fiduciary obligation to the Borrower with respect to such
information; provided, that the disclosure of any such information to any Lenders or prospective Lenders or participants or prospective participants or Specified Counterparties referred to above shall be made subject to the acknowledgment and
acceptance by such Lender or prospective Lender or participant or prospective participant or Specified Counterparty that such information is being disseminated on a confidential basis in accordance with the standard syndication process of the
Arranger or customary market standards for dissemination of such types of information; provided, further, that the foregoing obligations of the Commitment Parties shall remain in effect until the earlier of (i) two years from the
date hereof, and (ii) the execution and delivery of the Credit Documentation by the parties thereto, at which time any confidentiality undertaking in the Credit Documentation shall supersede the provisions in this paragraph. 

9. Miscellaneous. This Commitment Letter shall not be assignable by you or, except as contemplated by Section 2 above, us
without our or your, as applicable, prior written consent (and any purported assignment without such consent shall be null and void), is intended to be solely for the benefit of the parties hereto and is not intended to confer any benefits upon, or
create any rights in favor of, any person other than the parties hereto and the indemnified persons; provided that, we may assign our commitments and agreements hereunder in whole or in part, to any of our respective affiliates;
provided, further, that except with respect to assignments to Morgan Stanley Bank, N.A., or assignments made in compliance with Section 2 above, MSSF will not be released from any of its obligations hereunder in connection with an
assignment of its obligations to its affiliates. This Commitment Letter may not be amended or waived except by an instrument in writing signed by you and us. This Commitment Letter may be executed in any number of counterparts, each of which shall
be an original, and all of which, when taken together, shall constitute one agreement. Delivery of an executed signature page of this Commitment Letter by electronic transmission shall be effective as delivery of a manually executed counterpart
hereof. This Commitment Letter and the Fee Letter are the only agreements that have been 

  
 9 

 
entered into among us with respect to the Facility and set forth the entire understanding of the parties with respect thereto. No individual has been authorized by any Commitment Party or its
affiliates to make any oral or written statements that are inconsistent with this Commitment Letter or the Fee Letter. 
 Each of the
parties hereto agrees that this Commitment Letter is a binding and enforceable agreement with respect to the subject matter contained herein, including an agreement to negotiate in good faith the Credit Documentation by the parties hereto in a
manner consistent with this Commitment Letter, it being acknowledged and agreed that the commitments provided hereunder are subject to conditions precedent as provided herein. 

The compensation, reimbursement, indemnification, confidentiality, syndication, information and clear market provisions contained herein and
in the Fee Letter shall remain in full force and effect regardless of whether Credit Documentation shall be executed and delivered and notwithstanding the termination of this Commitment Letter or our commitments hereunder; provided, that your
obligations hereunder, other than with respect to the compensation, reimbursement, indemnification, confidentiality, syndication, information and clear market provisions, shall automatically terminate and be superseded by the provisions of the
Credit Documentation upon the effectiveness thereof; provided, further, that, in the case of the syndication, information, and clear market provisions, such provisions shall terminate upon the later of the Funding Date and the
Syndication Date. You may terminate our commitments to the Facility hereunder at any time subject to the provisions of the immediately preceding sentence. 

If the foregoing correctly sets forth our agreement, please indicate your acceptance of the terms hereof and the Fee Letter by returning to us
executed counterparts hereof and of the Fee Letter prior to 11:59 p.m. (New York City time), June 2, 2014. If the Commitment Letter and Fee Letter have not been executed and returned as described in the preceding sentence by such earlier
time, then the Commitment Parties’ offer hereunder shall terminate at such earlier time. After your execution and delivery to us of this Commitment Letter and the Fee Letter, our outstanding commitments with respect to the Facility in this
Commitment Letter shall automatically terminate (if not terminated earlier by you) upon the earliest to occur of (i) the execution and delivery of the Credit Documentation for the Facility by all parties thereto, (ii) the Commitment
Termination Date, if the applicable Credit Documentation shall not have been executed and delivered by all parties thereto by such date, (iii) abandonment or withdrawal of the Offer by you or lapse of the Offer (other than in connection with
the execution of the Merger Agreement or the effectiveness of the Scheme), in each case when publicly disclosed by you (A) pursuant to a public filing with the SEC or (B) in an official press release issued by you; and
(iv) termination by you of your obligations under the Merger Agreement to consummate the Merger when publicly disclosed by you (A) pursuant to a public filing with the SEC or (B) in an official press release issued by you. 

  
 10 

 We are pleased to have been given the opportunity to assist you in connection with this important
financing. 
  

					
	Very truly yours,
	
	MORGAN STANLEY SENIOR FUNDING, INC.
		
	By:	 	 /s/ Anish Shah

		 	Name:	 	Anish Shah
		 	Title:	 	Authorized Signatory

  

					
	
	Accepted and agreed to as of the date first written above by:
	
	ENDURANCE SPECIALTY HOLDINGS LTD.
		
	By:	 	 /s/ John V. Del Col

		 	Name:	 	John V. Del Col
		 	Title:	 	General Counsel

  
 11 

 Exhibit A 

PROJECT SAIL 
 364-DAY SENIOR
UNSECURED BRIDGE TERM LOAN FACILITY 
 Summary of Terms and Conditions 

June 2, 2014 
 Capitalized terms not
otherwise defined herein shall have the same meaning as specified with respect thereto in the Commitment Letter to which this Exhibit A is attached. 
  

					
	I. 	  	PARTIES	  	
			
		  	Borrowers:	  	Easter Specialty Holdings Ltd., a Bermuda exempted company (the “Borrower”).
			
		  	Sole Lead Arranger and Sole Bookrunner:	  	  
 Morgan Stanley Senior Funding, Inc. (“MSSF”) will act
as sole lead arranger and sole bookrunner for the Facility (in such capacities, the “Arranger”).

			
		  	Administrative Agent:	  	MSSF will act as the sole and exclusive administrative agent for the Facility (in such capacity, the “Administrative Agent”).
			
		  	Lenders:	  	A syndicate of banks, financial institutions and other entities, including MSSF and/or any of its affiliates, arranged by the Arranger in accordance with the terms of the Commitment Letter to which this Exhibit A is attached
(collectively, the “Lenders”).
			
	II.	  	THE FACILITY	  	
			
		  	Type and Amount of Facility:	  	364-day senior unsecured bridge term loan facility in the amount of $1,000,000,000 (the “Facility”).
			
		  	Availability:	  	The loans (the “Loans”) shall be made in a single drawing on the Closing Date subject to satisfaction or waiver of the express conditions precedent set forth in the Commitment Letter and Exhibit B attached thereto
and any undrawn commitments under the Facility shall automatically be terminated on the Funding Date.
			
		  	Maturity:	  	The Loans shall mature and be payable in full on the date that is 364 days after the Funding Date.
			
		  	Purpose:	  	The proceeds of the Loans shall be used on the Closing Date (directly or indirectly through a payment agent on behalf of the shareholders of the Target) to finance the Transactions and fees and expenses in connection
therewith.

							
		
	III.	  	CERTAIN PAYMENT PROVISIONS
			
		  	Fees and Interest Rates:	  	As set forth on Annex I to this Exhibit A.
			
		  	Optional Prepayments:	  	The Loans may be prepaid by the Borrower without premium or penalty (other than the payment of customary LIBO Rate breakage amounts) in minimum amounts and upon notice to be agreed upon. Loans prepaid may not be
reborrowed.
			
		  	Mandatory Prepayments:	  	The following amounts shall be applied to prepay the Loans (and, prior to the Funding Date, the commitments under the Facility, pursuant to the Commitment Letter and Credit Documentation, shall be automatically and
permanently reduced by such amounts):
				
		  		  	(a)	  	100% of the net cash proceeds of any sale or issuance of debt securities or incurrence of other debt (other than Excluded Debt (as defined below)) and equity securities or equity-linked securities (other than issuances pursuant to
employee stock plans and other than Excluded Equity), in each case on or after the date of the Commitment Letter by the Borrower or any of its subsidiaries;
				
		  		  	(b)	  	100% of the net cash proceeds (for any single transaction or series of related transactions which are above $50,000,000 and to the extent not reinvested or committed to be reinvested within six months following receipt) of any sale
or other disposition (including as a result of casualty or condemnation) in each case on or after the date of the Commitment Letter by the Borrower or any of its subsidiaries of any assets, except for the sale of investments in the ordinary course
of business, and subject to other exceptions to be agreed; and
				
		  		  	(c)	  	100% of the net cash proceeds of any sale or other disposition following the Funding Date of the equity securities or equity linked securities of the Target owned directly or indirectly by the Borrower that are acquired by the
Borrower in the Offer other than Unrestricted Margin Stock (as defined below).
			
		  		  	For the purpose hereof, (i) “Excluded Debt” means (A) intercompany debt among the Borrower and/or its subsidiaries, (B) existing ordinary course foreign credit lines (including the non-US dollar
collateralized letter of credit facility with ANZ Bank) and a new approximately $50,000,000 Canadian dollar collateralized letter of credit facility, (C) credit extensions under the Existing Credit Agreement up to the existing commitments thereunder
as of the date hereof and any refinancing or replacement of the Existing Credit Agreement up to the amount of such commitments, (D) any securities issued to refinance or replace the 6.15% Senior Notes, due 2015, in an aggregate principal amount of
$200,000,000, issued pursuant to that certain

  
 - 2 - 

							
		  		  	Second Supplemental Indenture, dated as of October 17, 2005 between Endurance Specialty Holdings Ltd., as Issuer, and The Bank of New York, as Trustee, (E) any debt incurred to refinance or replace any indebtedness
of the Target Business assumed in connection with the Acquisition (but only to the extent the Transactions would trigger a change of control prepayment event pursuant to, or would cause a default under, the terms of such indebtedness as in effect on
the date hereof), (F) other debt in an aggregate principal amount up to $50,000,000, and (G) any Excluded Equity; and (ii) “Excluded Equity” means all equity or equity-linked securities, including mandatorily exchangeable or
convertible securities (A) issued at a time when the consolidated tangible net worth of the Borrower without giving effect to the Acquisition is less than, or projected to be less than, $2,825,000,000, to the extent such consolidated tangible net
worth, after giving pro forma effect to such issuance, does not exceed $2,825,000,000; provided that the gross proceeds of any such issuance does not exceed $250,000,000, (B) issued and privately placed with the Borrower’s Chief
Executive Officer and yielding gross proceeds of up to $25,000,000 or (C) issued to fund any increase in the cash portion of the aggregate consideration payable in connection with the Acquisition; provided that the gross proceeds of any such
issuance does not exceed $75,000,000.
			
		  		  	Amounts prepaid pursuant to any mandatory prepayment of the Loans may not be reborrowed.
			
		  		  	The commitments under the Facility, pursuant to the Commitment Letter and the Credit Documentation, shall terminate on the earliest to occur of (i) the Commitment Termination Date, (ii) abandonment or withdrawal of the
Offer by the Borrower or lapse of the Offer (other than in connection with the execution of the Merger Agreement or the effectiveness of the Scheme), in each case when publicly disclosed by the Borrower (A) pursuant to a public filing with the SEC
or (B) in an official press release issued by the Borrower and (iii) termination by the Borrower of the Borrower’s obligations under the Merger Agreement when publicly disclosed by the Borrower (A) pursuant to a public filing with the SEC or
(B) in an official press release issued by the Borrower.
				
	IV.	  	CERTAIN CONDITIONS	  		  	
		
		  	Conditions to Availability of Loans:
			
		  		  	The Facility shall be available in a single drawing on the Closing Date subject to satisfaction (or waiver) of the express conditions precedent set forth in the Commitment Letter and Exhibit B attached thereto.

  
 - 3 - 

					
	V.	 	CERTAIN DOCUMENTATION MATTERS
			
		 		  	The Credit Documentation shall be based on and substantially similar to the Credit Agreement dated as of April 19, 2012 among the Borrower, certain of its subsidiaries named therein, JPMorgan Chase Bank, N.A. as administrative
agent, and the other agents and lenders party thereto (the “Existing Credit Agreement”) (except as otherwise provided in this Term Sheet and subject to modifications to reflect the unsecured nature of the Facility, the Transactions,
the size, proposed operational requirements of the Borrower and its subsidiaries (after giving effect to the Transactions) and such other modifications as shall have been agreed with the Arranger) and shall contain only the representations,
warranties, covenants and events of default set forth below (collectively, the “Documentation Principles”). Notwithstanding anything set forth herein to the contrary, for so long as any securities of the Target constitute
“margin stock” within the meaning of Regulation U, the restrictions on liens and certain other covenants and agreements set forth in the Credit Documentation shall not apply to such securities to the extent the value of such securities,
together with the value of all other margin stock held by the Borrower and its subsidiaries, exceeds 25% of the total value of all assets subject to such covenants and agreements (such margin stock the value of which exceeds 25% of the total value
of all such assets being referred to herein as “Unrestricted Margin Stock”).
			
		 	Representations and	  	
		 	Warranties:	  	Corporate status; corporate power and authority; no contravention of laws, agreements or organizational documents; litigation and contingent liabilities; use of proceeds, margin regulations; approvals; inapplicability of Investment
Company Act, true and complete disclosure; financial condition, financial statements; tax returns and payments; compliance with ERISA; subsidiaries; capitalization; indebtedness; compliance with statutes, regulations, rules and orders of
governmental bodies; insurance licenses; USA Patriot Act, FCPA, OFAC; and solvency as to the Borrower, subject for the avoidance of doubt, in the case of each of the foregoing representations and warranties, to exceptions, qualifications and
materiality consistent with the Documentation Principles. The foregoing representations and warranties shall apply to the Borrower and its subsidiaries prior to giving effect to the Acquisition. In the event of a Negotiated Transaction, the Borrower
shall in addition make the Merger Agreement Representations in the Merger Agreement as may be modified in accordance with the terms of Exhibit B (and no other representations with respect to the Target Business) with respect to the Target
Business.
			
		 	Affirmative Covenants:	  	Information covenants, including annual financial statements, quarterly financial statements, officer’s certificates, notice of default or litigation, other statements and reports, SEC filings, insurance reports and filings,
and other information; books, records and inspections; insurance; payment of taxes;

  
 - 4 - 

					
		 		  	maintenance of existence; compliance with statutes, regulations, rules and orders of governmental bodies; ERISA; maintenance of property; maintenance of licenses and permits; claims paying ratings; end of fiscal years, fiscal
quarters; further assurances; information as to the Acquisition; and consummation of Second-Step Merger or compulsory acquisition, if any, subject for the avoidance of doubt, in the case of each of the foregoing covenants, to exceptions,
qualifications and materiality consistent with the Documentation Principles.
			
		 	Financial Covenants:	  	(1) Minimum consolidated tangible net worth of not less than $1,800,000,000 at any time.
			
		 		  	(2) Maximum leverage ratio of not greater than 0.35:1.00, increasing to 0.40:1.00 to the extent a corresponding change is made to the Existing Credit Agreement.
			
		 	Negative Covenants:	  	Limitations on: changes in business; consolidations, amalgamations, mergers, sales of assets and acquisitions; liens; indebtedness; issuance of stock; dissolution; restricted payments; transactions with affiliates; private acts; and
restrictions on transfers, subject for the avoidance of doubt, in the case of each of the foregoing covenants, to exceptions (including “baskets”), qualifications and materiality consistent with the Documentation
Principles.
			
		 	Events of Default:	  	Nonpayment of principal when due, nonpayment of interest, fees or other amounts after a grace period and/or notice consistent with the Documentation Principles; material inaccuracy of representations and warranties; violation of
covenants (subject, in the case of certain affirmative covenants, to a grace period to be agreed upon); cross payment default and cross event of default, in each case subject to materiality thresholds; bankruptcy events; certain ERISA events,
subject to materiality thresholds; material judgments; insurance licenses, subject to a material adverse effect qualifier; and change of control.
			
		 	Voting:	  	Amendments and waivers with respect to the Credit Documentation shall require the approval of Lenders (other than defaulting Lenders) holding not less than a majority of the aggregate amount of the Loans and commitments, except that
(a) (i) reductions in the amount or extensions of the scheduled date of final maturity of any Loan of any Lender shall require the consent of such Lender, (ii) reductions in the rate of interest or any fee or extensions of any due
date thereof owed to any Lender shall require the consent of such Lender, (iii) increases in the amount or extensions of the expiry date of any Lender’s commitment shall require the consent of such Lender and (iv) modifications to the
pro rata provisions of the Credit Documentation shall require the consent of each Lender directly affected thereby and (b) the consent of 100% of the Lenders shall be required with respect to modifications to any of the voting
percentages.

  
 - 5 - 

					
		 	Defaulting Lenders:	  	The Credit Documentation will contain customary provisions in respect of defaulting Lenders.
			
		 	Assignments and	  	
		 	Participations:	  	The Lenders shall be permitted to assign (other than to the Borrower, its affiliates or to any Disqualified Institution (as defined below), a natural person or to a defaulting Lender) all or a portion of their Loans and commitments
with the consent (which consent, following the Funding Date, shall not be unreasonably withheld or delayed) of (a) the Borrower, provided that, following the Funding Date, such consent shall not be required if (i) the assignee is a
Lender, an affiliate of a Lender or an approved fund or a Permitted Assignee or (ii) an event of default under the Credit Documentation has occurred and is continuing, and (b) the Administrative Agent, unless a Loan is being assigned to an
existing Lender, an affiliate thereof or an approved fund. In the case of partial assignments (other than to another Lender or to an affiliate of a Lender), the minimum assignment amount shall be $10,000,000, unless otherwise agreed by the Borrower
(unless, following the Funding Date, an event of default has occurred and is continuing) and the Administrative Agent. Following the Funding Date, if the consent of the Borrower is required in connection with any assignment, it shall be deemed to
have provided such consent unless it has notified the Administrative Agent of its refusal to give such consent within ten (10) business days of receiving written request for its consent to such assignment.
			
		 		  	The Lenders shall also be permitted to sell participations in their Loans (except to a Disqualified Institution or a natural person). Participants shall have the same (but no greater) benefits as the Lenders with respect to yield
protection and increased cost provisions. Voting rights of participants shall be limited to those matters with respect to which the affirmative vote of the specific Lender from which it purchased its participation would be required as described
under “Voting” above.
			
		 		  	Pledges of Loans in accordance with applicable law shall be permitted without restriction. Promissory notes shall be issued under the Facility only upon request.
			
		 		  	“Disqualified Institutions” shall mean (i) those banks, financial institutions or other persons separately identified in writing by the Borrower prior to the date hereof, (ii) bona fide competitors of the
Borrower or its subsidiaries identified in writing by the Borrower from time to time or (iii) in the case of clauses (i) and (ii), affiliates of any such person. The Credit Documentation shall contain provisions on terms to be agreed
(i) providing that the Administrative Agent shall not have any liability for monitoring or ensuring compliance with provisions relating to Disqualified Institutions, (ii) giving assignors and assignees access to the list of Disqualified
Institutions and (iii) requiring assignees to make a representation that it is not a Disqualified Institution, and allowing the Administrative Agent and assigning lender to rely on such representation.

  
 - 6 - 

					
		 	Yield Protection:	  	The Credit Documentation shall contain customary provisions (a) protecting the Lenders against increased costs or loss of yield resulting from changes in reserve, tax, capital adequacy and other requirements of law
(provided, that for the purposes of determining a change in law, the Dodd-Frank Wall Street Reform and Consumer Protection Act and Basel III, and all requests, rules, guidelines or directives promulgated under, or issued in connection with,
either of the foregoing, shall be deemed to have been introduced or adopted after the date of the Credit Documentation, regardless of the date enacted, adopted or issued) and from changes in withholding or other taxes (other than franchise or income
taxes); provided that with respect to increased costs or capital adequacy, any such Lender shall only be entitled to seek such additional amounts if such Lender is generally seeking the payment of similar additional amounts from similarly
situated borrowers in comparable credit facilities and (b) indemnifying the Lenders for “breakage costs” incurred in connection with, among other things, any payment or prepayment of, or failure to borrow, a LIBOR Loan (as defined in
Annex I) on a day other than the last day of an interest period with respect thereto.
			
		 	 Expenses and
 Indemnification:
	  	  
 The Borrower shall pay all reasonable and documented out-of-pocket
expenses of the Administrative Agent and the Arranger associated with the syndication of the Facility and the preparation, execution and delivery of the Credit Documentation as provided in the Commitment Letter. The Borrower shall pay (a) all
reasonable and documented out-of-pocket expenses of the Administrative Agent in connection with the administration of the Credit Documentation and any amendment or waiver with respect thereto (including, without limitation, the reasonable fees,
disbursements and other charges of one counsel) and (b) all reasonable and documented out-of-pocket expenses of the Administrative Agent and the Lenders (including, without limitation, the fees, disbursements and other charges of one counsel
for the Administrative Agent and all Lenders and, if reasonably required, one local counsel to all such persons as necessary in each appropriate jurisdiction and, solely in the case of a conflict of interest, one additional counsel to the affected
persons taken as a whole in each applicable jurisdiction) in connection with the enforcement of the Credit Documentation.

			
		 		  	The Administrative Agent, the Arranger and the Lenders (and their affiliates and their respective officers, directors, employees, advisors and agents) will be indemnified and held harmless against, any loss, liability or claim
incurred in respect of the financing contemplated hereby or the use or the proposed use of proceeds thereof, and will be reimbursed by the Borrower within 30 days of written demand for any reasonable and documented out-of-pocket expenses incurred in
connection with investigating

  
 - 7 - 

					
		 		  	or defending any such Proceeding, including, the reasonable fees and expenses of one outside counsel to all such indemnified persons taken as a whole, if reasonably required one local counsel to all such indemnified parties as
necessary in each appropriate jurisdiction and, solely in the case of a conflict of interest, one additional counsel to the affected indemnified persons taken as a whole in each applicable jurisdiction, provided that the foregoing indemnity
will not, as to any indemnified person, apply to losses, claims, damages, liabilities or related expenses to the extent (i) and for so long as, they are found by a final judgment of the highest court of competent jurisdiction to have considered such
matter to arise from the willful misconduct, bad faith or gross negligence of such indemnified person or its affiliates or from the material breach of the Credit Documentation by such indemnified person or its affiliates or (ii) they arise from any
dispute solely among indemnified persons and not arising from any act or omission by the Borrower, the Target Business or any of their affiliates, except to the extent an indemnified person was acting in its capacity as Administrative Agent,
Arranger or other similar role.
			
		 	Governing Law and Forum:	  	New York; provided however, that, on or prior to the Closing Date, the interpretation of the definition of “Combined Material Adverse Effect” shall be governed by, and construed in accordance with, the
laws of the State of Delaware; provided further, however, that, if a Merger Agreement is entered into and pursuant to such Merger Agreement the laws of a jurisdiction other than the State of Delaware would govern the
interpretation of any definition therein of “Material Adverse Effect” or of any similar term, then the law of such jurisdiction shall govern the interpretation of the definitions of “Combined Material Adverse
Effect” and “Merger Agreement Representations” to the extent satisfactory to the Arranger at or prior to the time such Merger Agreement is executed (it being understood that the laws of Bermuda and the laws of the State of
New York are satisfactory to the Arranger). Each party to the Credit Documentation will waive the right to trial by jury and will consent to the exclusive jurisdiction of the state and federal courts located in The Borough of Manhattan, The City of
New York.
		 		  	
		 	Counsel to the	  	
		 	Administrative Agent and the Arranger:	  	  
 Davis Polk & Wardwell LLP.

  
 - 8 - 

 Annex I 

Interest and Certain Fees 
  

			
	Interest Rate Options:	  	The Borrower may elect that the Loans bear interest at a rate per annum equal to:
		
		  	 (i)     the ABR plus the Applicable Margin; or

		
		  	 (ii)    the Adjusted LIBO Rate plus the Applicable Margin.

		
		  	As used herein:
		
		  	“ABR” means, for any day, a fluctuating rate per annum equal to the highest of (i) the federal funds effective rate from time to time plus 0.50%, (ii) the rate of interest per annum from time to time published
in the “Money Rates” section of The Wall Street Journal as being the “Prime Lending Rate” or, if more than one rate is published as the Prime Lending Rate, then the highest of such rates (the “Prime Rate”) (each
change in the Prime Rate to be effective as of the date of publication in The Wall Street Journal of a “Prime Lending Rate” that is different from that published on the preceding domestic business day); provided, that in the event
that The Wall Street Journal shall, for any reason, fail or cease to publish the Prime Lending Rate, the Administrative Agent shall choose a reasonably comparable index or source to use as the basis for the Prime Lending Rate and (iii) the one month
Adjusted LIBO Rate plus 1.00%. Each change in any interest rate provided for herein based upon the ABR resulting from a change in the Prime Lending Rate, the federal funds effective rate or the Adjusted LIBO Rate shall take effect at the time of
such change in the Prime Lending Rate, the federal funds effective rate, or the Adjusted LIBO Rate, respectively.
		
		  	“Adjusted LIBO Rate” means the LIBO Rate, as adjusted for statutory reserve requirements for eurocurrency liabilities (if any).
		
		  	“Applicable Margin” means a percentage determined in accordance with the pricing grid attached hereto as Annex I-A (the “Pricing Grid”).
		
		  	“LIBO Rate” means the rate for eurodollar deposits in the London interbank market for a period of one, two, three or six months, in each case as selected by the Borrower, appearing on Page LIBOR01 of the Bloomberg
screen.
		
	Interest Payment Dates:	  	In the case of Loans bearing interest based upon the ABR (“ABR Loans”), quarterly in arrears on the last business day of each March, June, September and December.
		
		  	In the case of Loans bearing interest based upon the Adjusted LIBO Rate (“LIBOR Loans”), on the last day of each relevant

			
		  	interest period and, in the case of any interest period longer than three months, on each successive date three months after the first day of such interest period.
		
	Commitment Fees:	  	The Borrower shall pay, or cause to be paid, commitment fees (the “Commitment Fees”) to each Lender under the Facility calculated at a rate per annum equal to 0.20% (increasing to 0.30% from December 31, 2014) on
the daily average undrawn commitments of such Lender under the Facility, accruing during the period commencing on the later of (i) the date that is 60 days following the date of the Commitment Letter and (ii) the date of execution of the credit
agreement for the Facility, payable quarterly in arrears and upon repayment or termination of the Facility.
		
	Duration Fees:	  	The Borrower shall pay, or cause to be paid, duration fees (the “Duration Fees”) for the account of each Lender in amounts equal to the percentage as determined in accordance with the grid below, of the principal
amount of the Loan of such Lender outstanding at the close of business, New York City time, on each date set forth in the grid below, payable on each such date:

 

											
	Duration Fee	 
	90 days after the
Funding Date	 	 	180 days after the
Funding Date	 	 	270 days after the
Funding Date	 
	 	0.50	% 	 	 	0.75	% 	 	 	1.00	% 

  

			
	Default Rate:	  	A rate per annum equal to (i) in the case of overdue principal of any Loan, 2% above the rate otherwise applicable thereto or (ii) in the case of any other overdue amount, 2% above the rate applicable to ABR Loans, with such
interest being payable on demand.
		
	Rate and Fee Basis:	  	All per annum rates shall be calculated on the basis of a year of 360 days (or 365/366 days, in the case of ABR Loans the interest rate payable on which is then based on the Prime Rate) for actual days elapsed.

  
 - 2 - 

 Annex I-A 

PROJECT SAIL 
 Pricing Grid

  

																																	
	 Borrower’s Index Debt Rating (S&P or
Moody’s)
	  	Applicable Margin	 
	  	Funding Date through
89 days after Funding
Date	 	  	90 days after Funding
Date through 179
days after Funding
Date	 	  	180 days after
Funding Date through
269 days after
Funding Date	 	  	270 days after
Funding Date and
thereafter	 
	  	ABR
Loans	 	  	LIBOR
Loans	 	  	ABR
Loans	 	  	LIBOR
Loans	 	  	ABR
Loans	 	  	LIBOR
Loans	 	  	ABR
Loans	 	  	LIBOR
Loans	 
	 Rating Level 1: BBB+ / Baa1
	  	 	50.0 bps	  	  	 	150.0 bps	  	  	 	75.0 bps	  	  	 	175.0 bps	  	  	 	100 bps	  	  	 	200 bps	  	  	 	150.0 bps	  	  	 	250.0 bps	  
	 Rating Level 2: BBB / Baa2
	  	 	62.5 bps	  	  	 	162.5 bps	  	  	 	87.5 bps	  	  	 	187.5 bps	  	  	 	112.5 bps	  	  	 	212.5 bps	  	  	 	162.5 bps	  	  	 	262.5 bps	  
	 Rating Level 3: BBB- / Baa3
	  	 	75.0 bps	  	  	 	175.0 bps	  	  	 	100.0 bps	  	  	 	200.0 bps	  	  	 	125.0 bps	  	  	 	225.0 bps	  	  	 	175.0 bps	  	  	 	275.0 bps	  
	 Rating Level 4: < BBB- / Baa3
	  	 	125.0 bps	  	  	 	225.0 bps	  	  	 	150.0 bps	  	  	 	250.0 bps	  	  	 	175.0 bps	  	  	 	275.0 bps	  	  	 	225.0 bps	  	  	 	325.0 bps	  

 In the event of a split rating, the higher rating shall apply, except that in the event of a split rating of more than one
level, the applicable rating shall be one level below the higher rating. In the event that debt ratings are no longer in effect, the pricing will be determined based on Rating Level 4. 

 Exhibit B 

PROJECT SAIL 
 364-DAY SENIOR
UNSECURED BRIDGE TERM LOAN FACILITY 
 Conditions Precedent to Availability of Loans 

Capitalized terms used herein and not defined herein shall have the same meaning as specified with respect thereto in the Commitment Letter to
which this Exhibit B is attached. 
 The extension of credit under the Facility on the Closing Date shall be conditioned upon satisfaction
of the following conditions precedent on or before the Commitment Termination Date: 
 1. In the case of a Two-Step Acquisition:
(a) the definitive documents to be filed with the Securities and Exchange Commission with respect to the commencement of the Offer (the “Offer Documents”) shall have been delivered to the Arranger prior to the commencement of
the Offer (or, in the case of any amendments, supplements or other modifications that are subsequently filed, prior to the filing thereof) and the terms and conditions thereof shall be in form and substance reasonably satisfactory to the Arranger,
it being understood that the terms and conditions set forth in the May 29, 2014 draft Form S-4 and the exhibits thereto provided to the Arranger on May 31, 2014 (as modified to describe certain arrangements with certain equity investors
pursuant to an agreement dated as of June 2, 2014 disclosed to the Arranger prior to the date of the Commitment Letter) (the “Signing Date S-4”) is in form and substance reasonably satisfactory to the Arranger, (b) the
conditions in the Offer Documents with respect to (i) approval of the shareholders of the Borrower, (ii) effectiveness of the registration statement with respect to the Offer Documents under the Securities Act of 1933, as amended,
(iii) listing of the shares of the Borrower to be issued to shareholders of the Target on the New York Stock Exchange, (iv) redemption of the rights issued pursuant to the Target’s shareholder rights plan (or the rendering of such
rights as being inapplicable to the Acquisition) and (v) regulatory approvals shall not have been altered, amended or otherwise changed or supplemented, or consent thereunder granted, in any case in a manner that is materially adverse to the
Arranger or the Lenders, without the prior written consent of the Arranger, not to be unreasonably withheld, delayed or conditioned, (c) there shall have been no (A) increase in the cash component of the aggregate consideration payable
with respect to the Target Shares (the “Acquisition Consideration”) above a level previously agreed between the Borrower and the Arranger or (B) reduction in the minimum tender condition, in each case without the prior written
consent of the Arranger, (d) there shall have been no reduction in the aggregate consideration payable in connection with the Acquisition in excess of 10% without the prior written consent of the Arranger, unless the commitments under the
Facility are reduced by an amount equal to 40% of the amount of any such reduction in the aggregate consideration, (e) the Offer shall have been consummated substantially concurrently with the funding of the Facility in accordance in all
material respects with material applicable laws and with the Offer Documents, (f) the Borrower shall have delivered notice in writing to the Arranger that (i) it intends to consummate the acquisition of the Target Shares not acquired in
the Offer under Section 102 or Section 103 of the Bermuda Companies Act as soon as practicable following consummation of the Offer, confirming in such notice that it has received sufficient acceptances in the Offer to effect such
acquisition and it is not aware of any legal or other impediment to the consummation of such acquisition or (ii) it intends to consummate the Second-Step Merger as soon as practicable following the consummation of the Offer, confirming in such
notice that it has received sufficient acceptances in the Offer to approve the Second-Step Merger and that it is not aware of any legal or other impediment to the consummation of the Second-Step Merger; and (g) in the case of a Negotiated
Transaction, the condition in Section 2(a) below shall have been satisfied. 
 2. In the case of a One-Step Merger: (a) Borrower
and Target shall have entered into the Merger Agreement and delivered an executed copy thereof to the Arranger prior to the Closing Date and the terms and conditions thereof and documentation related thereto shall be customary for transactions of
this type and the Arranger shall have been given a reasonable opportunity to review and comment thereon, provided that (i) the provisions (x) giving the Arranger and the Lenders the benefit of certain

 
lender protective provisions commonly known as “Xerox” provisions, such as, with respect to the Facility, exclusive New York forum, waiver of jury trial, limitation on damages, waiver
of claims not based in contract, making the Arranger and Lenders third-party beneficiaries of the foregoing, and no amendment of the foregoing without the written consent of the Arranger and the Lenders and (y) obligating Target to use
commercially reasonable efforts to assist with the financing under the Facility shall in each case be reasonably satisfactory to the Arranger, (ii) the Merger Agreement shall contain the conditions precedent referred to in Section 1(b)
above (to the extent applicable to a One-Step Merger), unless otherwise consented to by the Arranger (such consent not be unreasonably withheld, delayed or conditioned), (iii) the cash component of the Acquisition Consideration shall not exceed
the level previously agreed between the Borrower and the Arranger, without the prior written consent of the Arranger, and (iv) the aggregate consideration payable in connection with the Acquisition shall not be less than 10% below the amount
contemplated by the Signing Date S-4 unless the commitments under the Facility are reduced by an amount equal to 40% of the amount of any such reduction in the aggregate consideration, without the prior written consent of the Arranger, (b) the
Merger Agreement and the documentation relating thereto shall not have been altered, amended or otherwise changed or supplemented, or any consent thereunder granted, (x) in a manner that is materially adverse to the Arranger or the Lenders, in
each case without the prior written consent of the Arranger, not to be unreasonably withheld, delayed or conditioned, (y) to increase the cash component of the Acquisition Consideration above a level previously agreed between the Borrower and
the Arranger without the prior written consent of the Arranger, or (z) to reduce the aggregate consideration payable in connection with the Acquisition by an amount in excess of 10% above the amount contemplated by the Signing Date S-4 unless
the commitments under the Facility are reduced by an amount equal to 40% of the amount of any such reduction in the aggregate consideration without the prior written consent of the Arranger and (c) the One-Step Merger shall be consummated
substantially contemporaneously with the borrowing under the Facility in accordance in all material respects with all material applicable laws and with the terms described in the Merger Agreement. 

3. In the case of a Scheme: (a) the definitive documents with respect to the Scheme (the “Scheme Documents”) and the
terms and conditions thereof shall conform to the requirements of Bermuda law with respect to Schemes of Arrangement in Bermuda taking into account the unsolicited nature of the Scheme, (b) the Scheme Documents shall not have been altered,
amended or otherwise changed or supplemented, or consent thereunder granted (x) in a manner that is materially adverse to the Arranger or the Lenders, in each case without the prior written consent of the Arranger, not to be unreasonably
withheld, delayed or conditioned, (y) to increase the cash component of the Acquisition Consideration above a level previously agreed between the Borrower and the Arranger without the prior written consent of the Arranger and (z) to reduce
the aggregate consideration payable in connection with the Acquisition in excess of 10% (unless the commitments under the Facility are reduced by an amount equal to 40% of any such reduction in the aggregate consideration) without the prior written
consent of the Arranger, (c) the approval of the Target shall have been obtained in a manner consistent with the directions of the Supreme Court of Bermuda and the Supreme Court of Bermuda shall have sanctioned the Scheme and (d) the
Scheme shall become effective by the delivery of the order sanctioning the Scheme to the Registrar of Companies of Bermuda substantially contemporaneously with the borrowing under the Facility in accordance with applicable law and the Scheme
Documents (and written evidence thereof shall have been delivered to the Arranger). 
 4. There not occurring since December 31, 2013
any circumstance, change, occurrence, fact, condition, development or effect (other than any circumstance, change, occurrence, fact, condition, development or effect that has been disclosed prior to the date hereof in the most recent public filing
on Form 10-K, the most recent public filing on Form 10-Q, or any public filing on Form 8-K after December 31, 2013, of the Borrower or Target, as applicable (excluding any disclosure contained in any section entitled “Risk Factors”
“Forward-Looking Statements” or “Cautionary Statement Regarding Forward-Looking Statements” except to the extent any such disclosure is also contained in any other section of 

  
 - 2 - 

 
such filing on Form 10-K, Form 10-Q or 8-K)) that, individually or in the aggregate, has had or would reasonably be expected to have a Combined Material Adverse Effect. “Combined Material
Adverse Effect” means a material adverse effect on the financial condition, business, operations or results of operations of the Borrower, the Target and their respective subsidiaries, taken as a whole; provided that none of the following,
and no circumstance, change, occurrence, fact, condition, development or effect to the extent caused or resulting from the following, shall constitute or be taken into account, individually or in the aggregate, in determining whether a Combined
Material Adverse Effect has occurred: (1) changes or developments in the economy, credit, securities or capital markets or legislative, regulatory or political conditions generally in the United States, Bermuda or any other jurisdiction in
which the Borrower, the Target or any of their respective subsidiaries operates or United States, Bermuda or global financial markets; (2) changes, circumstances, occurrences, facts, conditions, developments or events generally affecting the
property catastrophe and property casualty insurance and reinsurance industries in the geographic areas in which the Borrower, the Target or any of their respective subsidiaries operate or underwrite insurance or reinsurance; (3) changes,
circumstances, occurrences, facts, conditions, developments or events resulting in liabilities under property catastrophe and property casualty insurance and reinsurance agreements to which the Borrower, the Target or any of their respective
subsidiaries is a party, including any effects resulting from any earthquake, hurricane, tornado, windstorm, flood, drought, volcano, pandemic, tsunami, terrorist act, act of war or other natural or man-made disaster; (4) the commencement,
occurrence or continuation of any war or armed hostilities; (5) changes in any applicable law, statute, ordinance, common law, arbitration award, or any rule, regulation, judgment, order, writ, injunction, decree, agency requirement or
published interpretation of any governmental or regulatory authority; (6) changes in generally accepted accounting principles or in statutory accounting principles (or local equivalents in the applicable jurisdiction) (or authoritative
interpretations thereof), including accounting and financial reporting pronouncements by the United States Securities and Exchange Commission, the National Association of Insurance Commissioners and the Financial Accounting Standards Board;
(7) any change or announcement of a potential or prospective change in the Borrower’s, the Target’s or any of their respective subsidiaries’ credit, financial strength or claims paying rating or A.M. Best & Company
rating or the ratings of any of the Borrower’s, the Target’s or any of their respective subsidiaries’ businesses or securities; (8) suspension in trading or a change in the trading prices or volume of shares of the Borrower
common shares or the Target common shares or any other securities of the Borrower or the Target or any of their respective subsidiaries; or (9) the failure to meet any internal or published revenue, earnings or other projections, forecasts or
predictions for any period ending after the date hereof, except (A) that in the case of the foregoing clauses (7), (8) and (9), such exceptions shall not prevent or otherwise affect a determination that any changes, state of facts,
circumstances or events underlying a failure described in any such clause has resulted in, or contributed to, a material adverse effect on the Borrower, the Target and their respective subsidiaries, taken as a whole, and (B) in the case of the
foregoing clauses (1), (2), (4), (5) or (6), to the extent those changes, state of facts, circumstances or events have a materially disproportionate adverse effect on the Borrower, the Target and their respective subsidiaries, taken as a whole,
relative to other similarly situated persons in the property catastrophe and property casualty insurance and reinsurance industries in similar geographic areas to those in which the Borrower, the Target and their respective subsidiaries operate or
underwrite insurance or reinsurance (in which case only the incremental disproportionate adverse effect or effects may be taken into account in determining whether or not a Combined Material Adverse Effect has occurred). 

5. (a) The rating for the Borrower’s senior unsecured long-term indebtedness for borrowed money, taking into account the Transactions,
shall be at least (i) Baa3 (with stable outlook) from Moody’s and (ii) BBB- (with stable outlook) from S&P, (b) the rating for the Borrower’s financial strength, taking into account the Transactions, shall be at least
(i) A- (with stable outlook) from S&P and (ii) A- (with stable outlook) from A.M. Best and (c) except in the case of a Negotiated Transaction, the consolidated tangible net worth of the Borrower and its subsidiaries, pro forma for
the Transactions, shall not be less than $3.9 billion (which, with respect to Target, will be calculated based on publicly available information of Target). 

  
 - 3 - 

 6. The Arranger shall have received (i) audited consolidated balance sheets and related
statements of income, shareholders’ equity and cash flows of the Borrower and its subsidiaries for the three most recent years ended on or prior to the date that is 90 days prior to the Closing Date, and unaudited consolidated balance sheets
and related statements of income, shareholders’ equity and cash flows of the Borrower and its subsidiaries for each subsequent fiscal quarter ended at least 40 days prior to the Closing Date, in each case prepared in conformity with U.S. GAAP;
(ii) audited consolidated annual financial statements of the Target Business, as well as unaudited interim consolidated financial statements (which shall have been reviewed by the independent accountants for the Target Business as provided in
Statement on Auditing Standards No. 100) prepared in accordance with U.S. GAAP; provided that if a Merger Agreement has not been signed prior to the Closing Date, the financial statements referred to in this clause (ii) shall only
be required to be delivered to the extent publicly available; and (iii) customary pro forma financial statements, which in each case (subject to Rule 409 under the Securities Act of 1933, as amended) meet the requirements of Regulation S-X
under the Securities Act of 1933, as amended, and all other accounting rules and regulations of the SEC promulgated thereunder and required to be included in a Registration Statement under such Act of Form S-1; provided that if a Merger
Agreement has not been signed prior to the Closing Date, the pro forma financial statements referred to in this clause (iii) may be prepared based on publicly available information of the Target; provided that if such information in
clause (i) or (ii) above is filed with the SEC and publicly available, such information shall be deemed to have been delivered to the Arranger. 

7. The Lenders, the Administrative Agent, the Commitment Parties and the Arranger shall have received all fees required to be paid pursuant to
the Fee Letter, and all expenses to be paid or reimbursed pursuant to the Commitment Letter and for which invoices have been presented at least 3 business days prior to the Funding Date, on or before the Funding Date. 

8. The Lenders shall have received such customary legal opinions from such counsel to the Borrower as may be reasonably required by the
Administrative Agent, corporate organizational documents, good standing and officer certificates, a certificate from the chief financial officer of the Borrower as to the solvency of the Borrower as of the Funding Date in the form of Annex I to this
Exhibit B, a customary certificate of such chief financial officer demonstrating compliance with the financial covenants contained in the Credit Documentation on a pro forma basis for the Transactions, board of director resolutions, a borrowing
notice, and if requested at least 10 business days prior to the Funding Date with respect to PATRIOT Act and related compliance, information in response thereto to be delivered at least 3 business days prior to the Funding Date, in each case as is
customary for transactions of this type and reasonably satisfactory to the Administrative Agent. 
 9. There shall exist under the Credit
Documentation at the time of or after giving effect to the extensions of credit under the Facility on the Funding Date no (a) negative covenant default relating to indebtedness, liens, restricted payments, Private Acts (as defined in the
Existing Credit Agreement) (to the extent any such Private Act is materially adverse to the Lenders), merger or consolidation of the Borrower (other than the Acquisition), or sale of all or substantially all of the assets of the Borrower,
(b) financial covenant default, (c) cross acceleration (to the extent it constitutes a Material Adverse Effect (as defined in the Credit Documentation)), (d) payment default (after all applicable grace periods have expired) and
(e) bankruptcy event of default as set forth in Borrower’s Existing Credit Agreement. The Specified Representations shall be true and correct in all material respects and the Merger Agreement Representations, if any, shall be true and
correct in all material respects, in each case on the Closing Date after giving effect to the Transactions. For purposes hereof, “Specified Representations” means the representations and warranties of the Borrower relating to
(a) corporate existence, power and authority, in each case as they relate to entering into and performance of the relevant Credit Documentation by the Borrower, (b) the authorization, execution, delivery and enforceability of the Credit
Documentation, in each case as they relate to entering into and performance of the relevant Credit Documentation by the 

  
 - 4 - 

 
Borrower, (c) no conflicts of the Credit Documentation with (i) organizational documents of the Borrower, (ii) the Existing Credit Agreement or Borrower’s existing indentures
and (iii) any applicable law or order of any court or governmental authority or any material debt obligations of the Borrower not referenced in clause (ii) (in the case of this clause (iii), to the extent it would not have a material
adverse effect on the Borrower and its subsidiaries taken as a whole), (d) solvency as of the Funding Date of the Borrower and its Subsidiaries (other than Target and its Subsidiaries), (e) Federal Reserve margin regulations, (f) the
Investment Company Act, and (g) OFAC. For the avoidance of doubt, no representations or warranties shall be made as to or by the Target except to the extent of the Merger Agreement Representations if a Merger Agreement is entered into prior to
the Closing Date. 

  
 - 5 - 

 Annex I 

To Exhibit B 
 ENDURANCE
SPECIALTY HOLDINGS LTD. 
 SOLVENCY CERTIFICATE 

Date:             , 201   

This Solvency Certificate is delivered pursuant to Section [    ] of the Credit Agreement dated as of
[            ], 201   (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Endurance
Specialty Holdings Ltd., a Bermuda exempted company (the “Borrower”), the Lenders party thereto from time to time, Morgan Stanley Senior Funding Inc., as administrative agent, and certain other parties thereto. Capitalized terms
used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement. 
 The undersigned
Chief Financial Officer of the Borrower hereby certifies, solely in his capacity as an officer of the Borrower and not individually, to the best of his knowledge, as follows: 

1. As of the date hereof, immediately after giving effect to the [Transactions], on and as of such date the Borrower and its Subsidiaries
(other than the Target and its subsidiaries) on a consolidated basis will be able to pay their debts and liabilities, direct, subordinated, contingent, prospective or otherwise, as such debts and liabilities become due. 

2. As of the date hereof, the Borrower and its Subsidiaries (other than the Target and its subsidiaries) on a consolidated basis do not intend
to incur debts beyond their ability to pay such debts as they mature, taking into account the timing and amounts of cash to be received by the Borrower and such Subsidiaries and the timing and amounts of cash to be payable on or in respect of
Indebtedness of the Borrower and such Subsidiaries. 
 [Remainder of this page left intentionally blank] 

 IN WITNESS WHEREOF, the undersigned has executed this Solvency Certificate on the date first
written above. 
  

			
	ENDURANCE SPECIALTY HOLDINGS LTD.
		
	By:	 	  

		 	Name:
		 	Title:

 [Signature page to the Solvency Certificate]EX-10.2

 Exhibit 10.2 

EXECUTION COPY 
 AGREEMENT

 This AGREEMENT (this “Agreement”), dated as of June 2, 2014, is made and entered into by and among CVC Capital
Partners Advisory (U.S.), Inc. (“CVC”), GIC Special Investments Pte. Ltd. (“GIC” and together with CVC, the “Investors”), Endurance Specialty Holdings Ltd., a Bermuda exempted company (the
“Company”), and, solely for purposes of Sections 3, 4, 6, 7, 8, 9, 10, 11 and 12, CVC European Equity Partners V (A) L.P., CVC European Equity Partners V
(B) L.P., CVC European Equity Partners V (C) L.P., CVC European Equity Partners V (D) L.P., and CVC European Equity Partners V (E) L.P. (each a “CVC Investor” and collectively, the “CVC
Investors”), and Cliff Investment Pte. Ltd. (the “GIC Investor”). 
 RECITALS 

WHEREAS, pursuant to that certain Equity Commitment Letter, dated as of January 28, 2014 (the “Equity Commitment
Letter”), by and among the CVC Investors, the GIC Investor and the Company, the CVC Investors, through a single, newly formed investment vehicle organized as a Cayman Islands limited partnership (the “CVC Purchaser”), and
the GIC Investor, severally and not jointly, committed to purchase newly issued ordinary shares, par value $1.00 per share, of the Company (the “Ordinary Shares”), for an aggregate purchase price equal to $1.05 billion (the
“Aggregate Commitment”), on the terms and subject to the conditions described therein (the “Investment”), the proceeds of which were to be used to partially fund the cash portion of an acquisition by the Company of
Aspen Insurance Holdings Limited (“Aspen”) (the “Acquisition” and together with the Investment, the “Transaction”); 

WHEREAS, the CVC Investors, the GIC Investor and the Company desire to terminate the Equity Commitment Letter in accordance with
Section 3 hereof; 
 WHEREAS, the Company desires to reimburse the Investors for certain expenses incurred by the Investors, and
their respective “affiliates” (as such term is defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), in connection with the Transaction; and 

WHEREAS, in the event the Acquisition is consummated, the Company desires to grant the Equity Option Investors (as defined below) the Equity
Investment Option (as defined below), and a right of first refusal with respect to certain equity capital raises made by the Company in connection with the financing or refinancing of the cash portion of the consideration to be paid to Aspen
shareholders in the Acquisition. 

 NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements set
forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

Section 1. Equity Investment Option. 

(a) In the event the Company enters into a definitive written agreement to acquire or acquires 95% or more of the ordinary shares of Aspen on
a fully diluted basis (including, without limitation, by merger, consolidation, reorganization, exchange offer, scheme of arrangement, amalgamation or otherwise, or a series of related transactions) (an “Acquisition Transaction”) on
or prior to December 31, 2014, and such Acquisition Transaction closes pursuant to its terms (the date on which such Acquisition Transaction closes, the “Acquisition Transaction Closing Date”), CVC and its Permitted Assignees
(as defined below) (collectively, the “Equity Option Investors”) shall have the irrevocable right, but not an obligation, severally and not jointly, upon delivery of a written notice to the Company not later than 5:00 p.m., New York
City time, on the sixtieth (60th) day following the Acquisition Transaction Closing Date (such notice, the “Equity Investment Exercise Notice”), to elect to make an equity investment of $250,000,000 in the Company in the
aggregate (not more or less) (the “Equity Investment Amount”), via the structure and with the principal terms described in the term sheet attached hereto as Exhibit A (the “Equity Investment Option”). If an
equity investment is made by the Equity Option Investors pursuant to this Section 1(a), it shall be allocated among the Equity Option Investors as set forth in the Equity Investment Exercise Notice; provided, however, that
the allocation to any Permitted Assignee or its affiliates shall not exceed 35% of the Equity Investment Amount in any case. In no case shall the Equity Investment Option be assigned or allocated or participations or sub-participations be granted to
any person or entity other than the Equity Option Investors. For purposes of this Agreement, “Permitted Assignee” means any fund, investment vehicle or other entity managed, advised, controlled by, or under 80% common ownership with CVC
and their respective investment committees, boards of managers, boards of directors and general partners. 
 (b) In the event the Company
enters into a definitive written agreement with respect to or completes an Acquisition Transaction on or prior to December 31, 2014, and such Acquisition Transaction closes pursuant to its terms, the Equity Option Investors and their respective
Representatives (as defined below) shall be entitled to conduct reasonable due diligence on the combined company resulting from such Acquisition Transaction during the sixty (60) day period following the Acquisition Transaction Closing Date.
The Company shall cause its Representatives to reasonably cooperate with, and shall make the management of the combined company reasonably available to, the Equity Option Investors and their respective Representatives in connection with such due
diligence review. For purposes of this Agreement, “Representative” shall mean with respect to any person or entity, such person’s or entity’s directors, officers, employees, controlled affiliates, advisors, representatives and
agents. 
 (c) If the Equity Investment Option is duly exercised, the Company and the Equity Option Investors will negotiate in good faith
an investment agreement containing the principal terms set forth on Exhibit A attached hereto. 
 Section 2. Alternative
Transaction Fee. In the event any person or entity (other than the CVC Investors or their affiliates) enters into a definitive written agreement to acquire or acquires (including, without limitation, by merger, consolidation, reorganization,
exchange offer, scheme of arrangement, amalgamation or otherwise, or a series of related transactions) more than 40% of the capital stock of the Company on or prior to December 31, 2014, upon the closing of such transaction or series of related
transactions, the Company shall pay to CVC an amount equal to $26,250,000, less the amount of any expense reimbursement paid to CVC or GIC or any of their respective affiliates in connection with the Transactions. 

  
 2 

 Section 3. Equity Commitment Letter Termination and Related Matters. 

(a) Effective immediately, the Equity Commitment Letter shall be terminated, and except as set forth in Section 3(b) of this
Agreement no party thereto shall have any rights or obligations thereunder. As a result of the termination of the Equity Commitment Letter, (i) none of the CVC Investors, the CVC Purchaser, the GIC Investor, GIC or any of their respective
affiliates shall have any right or obligation to purchase any securities of the Company pursuant to the Equity Commitment Letter and (ii) the Company shall be free to pursue the Acquisition, including the financing thereof, in any manner it so
determines. 
 (b) Sections 5 (Indemnification), 7 (Confidentiality), 8 (Third Party Beneficiaries; Amendment; Waiver), 9 (Termination), 11
(Governing Law; Jurisdiction; Venue; Waiver of Jury Trial), 12 (No Recourse), 13 (Entire Agreement), 14 (Counterparts) and 15 (Notices) of the Equity Commitment Letter shall survive the termination thereof provided for under Section 3(a)
of this Agreement. 
 (c) To the fullest extent permitted by applicable law, each party hereto, on behalf of itself, its subsidiaries and
affiliates and their respective future, present and former directors, officers, shareholders, partners, members, employees, agents, attorneys, successors and assigns, hereby unequivocally, knowingly, voluntarily, unconditionally and irrevocably
waives, fully and finally releases, remises, exculpates, acquits and forever discharges each other party hereto, each other party’s subsidiaries and affiliates and their respective future, present and former directors, officers, shareholders,
partners, members, employees, agents, attorneys, successors and assigns from any and all actions, causes of action, suits, debts, accounts, bonds, bills, covenants, contracts, controversies, obligations, claims, counterclaims, setoffs, debts,
demands, damages, costs, expenses, compensation and liabilities of every kind and any nature whatsoever, in each case whether absolute or contingent, liquidated or unliquidated, known or unknown, and whether arising at law or in equity, which such
party had, has, or may have based upon, arising from, in connection with or relating to the Equity Commitment Letter, any agreement or instrument delivered in connection therewith or the transactions contemplated thereby; provided,
however, that the foregoing shall not limit the rights and obligations of the parties hereto (i) under this Agreement or (ii) under the Equity Commitment Letter which survive the termination thereof as provided in
Section 3(b) of this Agreement. Each party hereto shall refrain from, directly or indirectly, asserting any claim or demand or commencing, instituting, maintaining, facilitating, aiding or causing to be commenced, instituted or
maintained, any legal or arbitral proceeding of any kind against any person or entity released under this Section 3(c) based upon any matter released under this Section 3(c). 

(d) The Company, CVC and GIC shall agree to a public statement regarding (i) the Equity Commitment Letter and the termination thereof
and (ii) the transactions contemplated hereby (collectively, the “Covered Matters”). Other than with respect to the Covered Matters and customary background information regarding CVC or GIC, the Company shall provide to CVC or
GIC a copy of any public statement to be made by the Company with respect to CVC or GIC, as applicable, reasonably in advance of the publication thereof, and 

  
 3 

 
allow CVC or GIC, as the case may be, a reasonable opportunity to review and comment on such public statement, and shall consider such comments in good faith and incorporate any reasonable
comments timely provided, it being understood and agreed that the Company may repeat public statements made in accordance with this Section 3(d) without again providing them in advance to CVC or GIC, as the case may be. 

(e) None of CVC, the CVC Investors, GIC, or any of their respective affiliates or Representatives (in the case of any Representative, so long
as such person or entity is acting for or on behalf of the foregoing persons or entities) shall, from and after the date hereof through and including December 31, 2014, and during any additional period during which the Company is party to a
definitive written agreement with respect to an Acquisition Transaction (even if after December 31, 2014), without the consent of a majority of the Company’s Board of Directors, assist, advise, act in concert or participate with or
encourage others to, directly or indirectly: (i) acquire (or agree, offer, seek or propose to acquire, in each case, publicly or privately), by purchase, tender offer, exchange offer, agreement or business combination or in any other manner,
any ownership, including, but not limited to, beneficial ownership, as defined in Rule 13d-3 under the Exchange Act, of, or economic exposure to, any of the assets, liabilities, businesses or securities of Aspen or any direct or indirect subsidiary
thereof, or any rights or options (including through any economic, hedging or “short sale” transactions) to acquire such ownership or economic exposure (including from any third party) (provided, however, that this clause
(i) shall not prohibit any acquisition of securities of Aspen or any direct or indirect subsidiary thereof made in the ordinary course of CVC’s or GIC’s portfolio investment operations, which shall in no case include acquisitions in
the aggregate by CVC or GIC (together with its affiliates) in excess of 4.99% of the outstanding amount of any class of securities of Aspen or any direct or indirect subsidiary thereof) (provided that GIC and its affiliates (including its
public operations and its investment operations) will not own in excess of 9.9% of Aspen’ ordinary shares on an aggregate basis); (ii) publicly (or privately) offer to enter into, or publicly (or privately) propose, any merger, business
combination, recapitalization, restructuring or other extraordinary transaction with Aspen or any direct or indirect subsidiary thereof; (iii) initiate any shareholder proposal or the convening of a shareholders’ meeting of or involving
Aspen or any direct or indirect subsidiary thereof; (iv) solicit proxies (as such terms are defined in Rule 14a-1 under the Exchange Act), whether or not such solicitation is exempt pursuant to Rule 14a-2 under the Exchange Act, with respect to
any matter from, or otherwise seek to influence, advise or direct the vote of, holders of any shares of capital stock of Aspen or any securities convertible into, exchangeable for or exercisable for (in each case, whether currently or upon the
occurrence of any contingency) such capital stock, or make any communication exempted from the definition of solicitation by Rule 14a-1(l)(2)(iv) under the Exchange Act; (v) otherwise seek or propose to influence, advise, change or control the
management, board of directors (including proposing any director nominees), governing instruments, affairs or policies of Aspen or any direct or indirect subsidiary thereof; (vi) enter into any discussions, negotiations, agreements,
arrangements or understandings with any other person or entity (other than CVC, the CVC Investors, GIC or any of their respective affiliates subject to compliance with the foregoing clauses (i) through (vi)) with respect to any matter described
in the foregoing clauses (i) through (vi) or form, join or participate in a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) to vote, acquire or dispose of any securities of Aspen or any of its
subsidiaries; (vii) request that the Company (or any of its affiliates) amend, waive, grant any consent under or otherwise not enforce any provision of this Section 3(e); or (viii) make any public disclosure, or

  
 4 

 
take any action that could reasonably be expected to require the Investors or the Company to make a public disclosure, with respect to any of the matters set forth in this
Section 3(e), other than any public disclosure by CVC, the CVC Investors, GIC or any of their respective affiliates which is required by judicial or governmental order, discovery request, subpoena or similar compelled process (other than
any such process commenced by CVC, the CVC Investors, GIC or any of their respective affiliates). Notwithstanding the foregoing, CVC and the CVC Investors shall only be bound by the provisions of this Section 3(e) applicable to them and
their respective affiliates and Representatives, and GIC shall only be bound by the provisions of this Section 3(e) applicable to GIC and its affiliates and Representatives. 

Section 4. Expense Reimbursement. 

(a) The Company shall pay or reimburse CVC and GIC for 75% of all reasonable and documented out-of-pocket costs and expenses (including,
without limitation, due diligence expenses and fees and expenses of their respective outside counsel, accountants and other professionals and consultants) incurred by the CVC Purchaser, the CVC Investors, CVC European Equity V Limited (the
“CVC GP”), CVC, the GIC Investor and GIC in connection with evaluating, structuring or negotiating the Acquisition and the Investment (collectively, “Investor Expenses”) from November 1, 2013 through and
including the day prior to the date of this Agreement; provided, however, except as set forth in the following sentence, the aggregate amount payable or reimbursable to the Investors pursuant to this Section 4(a) shall not
exceed $3,000,000. Solely in the event the Company enters into a definitive written agreement with respect to, or completes, an Acquisition Transaction on or prior to December 31, 2014, then, upon (i) the closing of such Acquisition
Transaction or (ii) if the definitive written agreement with respect to such Acquisition Transaction is terminated in accordance with its terms and the Company receives a termination fee or any expense reimbursement in respect of such
termination, upon the receipt of such termination fee or expense reimbursement, the Company agrees to pay or reimburse CVC and GIC for 100% of their remaining Investor Expenses incurred since November 1, 2013 through and including the date of
the closing of such Acquisition Transaction or the termination of the definitive written agreement with respect thereto, as the case may be (including any success fee payable to Aon Benfield Securities, Inc. (“Aon”) in connection
with the Transaction and up to $150,000 to Aon for their reasonable and documented out-of-pocket costs and expenses relating to the financial advisory services provided to the Investors in connection with the Transaction, which shall not in any case
be in respect of any indemnification obligations), up to an amount that shall not exceed $5,400,000 in the aggregate (inclusive of any amounts paid or payable pursuant to the first sentence of this Section 4(a)); provided,
however, that the aggregate amount payable or reimbursable to the Investors pursuant to this sentence shall not exceed 75% of the amount of any such termination fee or expense reimbursement actually received by the Company in respect of such
termination. In no event shall the Company be required to pay any Investor Expenses pursuant to this Section 4(a) prior to the fifth (5th) business day after its receipt of reasonable documentation evidencing such Investor Expenses.

 (b) Other than as provided in Section 2 hereof, this Section 4 and Section 5 of the Equity Commitment
Letter (Indemnification), the Company shall have no obligation to pay any fees and expenses of CVC, GIC, the CVC Purchaser, the CVC Investors, CVC GP, the GIC Investor or any of their respective affiliates or Representatives in connection with the
Equity Commitment Letter or the transactions contemplated thereby. 

  
 5 

 Section 5. Right of First Refusal. 

(a) In the event the Company proposes to raise equity capital through the sale of equity securities or securities convertible into or
exchangeable or exercisable for equity securities of the Company or other equity-linked securities (“Equity Capital”) to a third party investor or investors (collectively, a “Third Party Investor”), the purpose of
which is to partially fund the cash portion of an acquisition of Aspen completed, or for which a definitive written agreement is entered into, on or prior to December 31, 2014, or to refinance any debt incurred by the Company in connection with
any such acquisition (only to the extent the proceeds of any such refinancing are specifically earmarked for such purpose) (a “Private Equity Capital Raise”), the Company shall deliver to CVC a written notice (such written notice, a
“First Refusal Notice”) stating that the Company proposes to conduct such Private Equity Capital Raise with such Third Party Investor and the material terms and conditions upon which the proposed Private Equity Capital Raise is to
be made (the date on which CVC receives the First Refusal Notice, the “Notice Date”). 
 (b) With respect to any proposed
Private Equity Capital Raise, the Equity Option Investors shall have the right (the “Right of First Refusal”), but not an obligation, to provide the Equity Capital for the full amount of such proposed Private Equity Capital Raise on
the terms and conditions set forth in the First Refusal Notice by CVC delivering an irrevocable written notice of such election (an “Acceptance Notice”) to the Company no later than ten (10) days following the Notice Date (the
“First Refusal Termination Date”); provided, however, in no event shall the Equity Option Investors have the right to provide Equity Capital to the Company in an aggregate amount in excess of the Aggregate Commitment.

 (c) Upon receipt of a duly delivered Acceptance Notice, the Company and CVC shall negotiate in good faith to consummate the Private
Equity Capital Raise within one hundred twenty (120) days of the delivery of such Acceptance Notice (which period may be extended upon the mutual agreement of the Company and CVC) (such period, as extended, the “First Refusal Closing
Period”). 
 (d) To the extent that the Company and the Equity Option Investors do not consummate such Private Equity Capital
Raise within the First Refusal Closing Period, the Acceptance Notice delivered by CVC shall be cancelled and be of no force or effect and the Company may proceed to complete any Private Equity Capital Raise in its discretion without any further
notice to, or rights of, the Equity Option Investors or their respective affiliates. 
 (e) In the event CVC does not duly exercise the
Right of First Refusal prior to the First Refusal Termination Date, the Company may proceed to closing the Private Equity Capital Raise with the Third Party Investor without any further notice to, or rights of, the Equity Option Investors or their
respective affiliates; provided, that (i) such Private Equity Capital Raise is on substantially the same terms and conditions set out in the First Refusal Notice and (ii) the closing of the Private Equity Capital Raise occurs no
later than one hundred twenty (120) days following the First Refusal Termination Date. 

  
 6 

 (f) If any of the foregoing requirements of Section 5(e) are not satisfied with
respect to the Private Equity Capital Raise being provided by the Third Party Investor, then, prior to the closing of such Private Equity Capital Raise or any new Private Equity Capital Raise, the Company shall provide a notice to CVC (which notice
shall be a new First Refusal Notice), which Private Equity Capital Raise shall then be subject to the Equity Option Investors’ right of first refusal and this Section 5 shall apply thereto. 

(g) Notwithstanding the foregoing, the Equity Option Investors shall have no right of first refusal as contemplated by this
Section 5 in connection with issuances or sales of Equity Capital (i) to John Charman or an affiliate thereof, up to $25,000,000, (ii) to the two investors (identified in an e-mail sent by Endurance’s outside counsel to
CVC’s outside counsel on May 31, 2014) or any of their respective affiliates, up to $100,000,000 in the aggregate, or (iii) in connection with a public offering of Company securities. 

Section 6. Successors and Assigns; Assignment. This Agreement shall be binding on the parties hereto and their respective
successors and permitted assigns. Neither this Agreement nor any right, benefit or obligation in or under this Agreement may be assigned by a party hereto without the prior written consent of the other parties hereto, except that CVC shall have the
right to assign its rights and obligations pursuant to Section 1 or Section 5 hereof to a Permitted Assignee effective upon concurrent written notice to the Company; provided that no such assignment shall relieve CVC of its
obligations hereunder. 
 Section 7. Entire Agreement. Other than the Confidentiality Agreement, dated November 17, 2013,
between the Company and CVC (including the related letter agreement, dated November 18, 2013, between CVC and GIC), which shall remain in full force and effect in accordance with their terms, this Agreement (including the Exhibit and Schedule
attached hereto) constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes any prior agreement or understanding between or among them (whether written or oral) with respect to such subject matter,
including but not limited to the Equity Commitment Letter. 
 Section 8. Governing Law; Jurisdiction; Venue; Waiver of Jury
Trial. 
 (a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to
contracts executed in and to be performed in that State, without giving effect to any conflict of law principles thereof that would require the application of the laws of another jurisdiction. Each party irrevocably and unconditionally consents to
submit to the exclusive personal jurisdiction of the courts of the State of New York and the United States of America, in each case located in the county of New York, New York, for such actions, suits or proceedings concerning the subject matter of
this Agreement (and agrees not to commence any action, suit or proceeding concerning the subject matter of this Agreement except in such courts). Notwithstanding the foregoing, any party may commence an action, suit or proceeding with any
governmental entity anywhere in the world for the sole purpose of seeking recognition and enforcement of a judgment of any court referred to in the preceding sentence. Each party irrevocably and unconditionally waives any objection to the laying of
venue of any action, suit or proceeding concerning the subject matter of this Agreement in the courts of the State of New York and the United States of America, in each case in the 

  
 7 

 
county of New York, New York, and further waives the right to, and agrees not to, plead or claim that any such action, suit or proceeding brought in any such court has been brought in an
inconvenient forum. Service of any process, summons, notice or document by U.S. registered mail to the applicable party’s address set forth in Section 10 herein (or in any other manner permitted by applicable law, including, in the
case of any CVC Investor or the CVC GP, to the extent appointed, their respective registered agent in the United States for service of process) shall be effective service of process for any action, suit or proceeding brought against any party
hereto, as applicable, in any court of competent jurisdiction concerning the subject matter of this Agreement. 
 (b) To the extent that
any party hereto, or the property of any party hereto, has or hereafter may have or acquire any immunity from jurisdiction of any court or arbitral tribunal or from any legal process (whether through service or notice, attachment prior to judgment,
attachment in aid of execution or otherwise) with respect to itself or its property by virtue of its relationship with, or any possible congruence with, any sovereign or sovereign entity, or any of a sovereign’s agents, representatives,
employees or other individuals, such party: (i) agrees that the execution, delivery and performance by it of this Agreement constitutes private and commercial acts done for private and commercial purposes; (ii) agrees that, should any
proceedings be brought against it or its assets in any jurisdiction in relation to this Agreement or any transaction contemplated hereby, including any action to enforce or execute upon a judgment or award arising out or relating to this Agreement,
such party is not entitled to any immunity in respect of its obligations under this Agreement, and no such immunity from such proceedings (including, without limitation, immunity from service of process from suit, from the jurisdiction of any court,
from an order or injunction of such court or the enforcement of same against its assets) shall be claimed by or on behalf of such party or with respect to its assets; (iii) waives, in any such proceedings, to the fullest extent permitted by
law, any right of immunity which it or any of its assets now has or may acquire in the future in any jurisdiction; (iv) consents generally to the giving of any relief or the issue of any process in any jurisdiction in connection with
proceedings permitted by Section 8(a) above (including, without limitation, pre-judgment attachment, post-judgment attachment, and the enforcement or execution against or in respect of any assets whatsoever irrespective of their use or
intended use of any order or judgment that may be made or given in connection therewith); and (v) specifies that, for the purposes of this provision, “assets” shall be taken as excluding “premises of the mission” as defined
in the Vienna Convention on Diplomatic Relations signed at Vienna, April 18, 1961, “consular premises” as defined in the Vienna Convention on Consular Relations signed in 1963, and military property or military assets or property of
such party. 
 (c) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY (WHETHER AT LAW, IN CONTRACT, IN TORT OR OTHERWISE) THAT MAY
ARISE UNDER OR RELATE TO THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
CONCERNING THE SUBJECT MATTER OF THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH

  
 8 

 
OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY
MAKES THIS WAIVER VOLUNTARILY AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8. 

Section 9. Counterparts. This Agreement may be executed in any number of counterparts, each such counterpart being deemed to be an
original instrument, and all such counterparts shall together constitute the same agreement. This Agreement and any signed agreement entered into in connection herewith or contemplated hereby, and any amendments hereto or thereto, to the extent
signed and delivered by facsimile, by electronic mail in “portable document format” (“.pdf”) form, or any other electronic transmission, shall be treated in all manner and respects as an original contract and shall be considered
to have the same binding legal effects as if it were the original signed version thereof delivered in person. 
 Section 10.
Notices. All notices, requests, demands and other communications given or made under this Agreement shall be in writing and shall be deemed to have been duly given or made: (a) as of the date delivered, when delivered personally;
(b) on the date the delivering party receives confirmation, if delivered by cable, telecopy or facsimile; (c) two (2) business day after being sent by an internationally recognized overnight courier service (providing proof of
delivery); or (d) three (3) business days after being mailed by certified or registered mail (return receipt requested, with postage prepaid), to the parties at the following addresses (or at such other address for a party as shall be
specified by like notice): 
 If to CVC or any CVC Investor, to: 

c/o CVC Capital Partners Advisory (U.S.), Inc. 

712 Fifth Avenue, 43rd Floor 

New York, NY 10019 

Attn:  Kamil M. Salame 

Fax:   (212) 265-2375 

with a copy (which copy shall not constitute notice) to: 

Weil, Gotshal & Manges LLP 

767 Fifth Avenue 

New York, NY 10153 

Attn:  Doug Warner 

Fax:   (212) 310-8007 

If to GIC or the GIC Investor, to: 

c/o GIC Special Investments Pte. Ltd. 

335 Madison Avenue, 24th Floor 

New York, NY 10017 

Attn:  R. Eric Wilmes 

Fax:   (212) 468-1901 

  
 9 

 With a copy (which copy shall not constitute notice) to: 

Sidley Austin LLP 

787 Seventh Avenue 

New York, NY 10019 

Attn:  Asi Kirmayer 

Fax:   (212) 839-5599 

If to the Company, to: 

c/o Endurance Services Limited 

750 Third Avenue 

New York, NY 10017 

Attn:  Daniel Lurie 

Fax:   (914) 206-4369 

With a copy (which copy shall not constitute notice) to: 

Skadden, Arps, Slate, Meagher & Flom LLP 

Four Times Square 

New York, NY 10036 

Attn:  Todd Freed 

Richard Grossman 

Fax:   (917) 777-2000 

The parties hereto agree and acknowledge that, in the event of a change of any notice address set forth above, such party shall notify in writing all other
parties hereto of such change no more than three (3) business days following such change. 
 Section 11. Third Party
Beneficiaries; Amendment; Waiver. Except as set forth in Section 3(c) and Section 12 of this Agreement and Section 5 of the Equity Commitment Letter, this Agreement may be relied upon only by the parties hereto and
nothing set forth in this Agreement shall be construed to confer upon or give any person other than the parties hereto any benefits, rights or remedies under or by reason of this Agreement, or any rights to enforce or to cause any party hereto to
enforce any provisions of this Agreement. No amendment of any provision of this Agreement will be valid and binding unless it is in writing and signed by each of the parties hereto. No waiver of any provision of this Agreement will be valid and
binding unless it is in writing and signed by the party against whom such waiver is sought to be enforced. No waiver by any party of any breach or violation of, or default under, this Agreement, whether intentional or not, will be deemed to extend
to any prior or subsequent breach, violation or default hereunder or affect in any way rights arising by virtue of any prior or subsequent such occurrence. No delay or omission on the part of any party in exercising any right, power or remedy under
this Agreement will operate as a waiver thereof. 
 Section 12. No Recourse. Notwithstanding anything that may be expressed or
implied in this Agreement, each of the parties hereto acknowledges and agrees that (a) notwithstanding that certain of the parties hereto may be partnerships, no recourse hereunder or under any documents or instruments delivered in connection
herewith may be had against (i) any current or 

  
 10 

 
future director, officer, agent or employee of any party hereto, (ii) any direct or indirect holder of any equity interests or securities of any party hereto (whether such holder is a
limited or general partner, member, shareholder or otherwise), or (iii) any affiliate of any party hereto, or any direct or indirect current or future director, officer, employee, partner, affiliate, member, controlling person, attorney or
representative of any of the foregoing (each such person or entity in the foregoing clauses (i), (ii) or (iii), a “Related Person”), in each case whether by the enforcement of any judgment or assessment or by any legal or
equitable proceeding, or by virtue of any statute, regulation or other applicable law, and (b) no personal liability whatsoever will attach to, be imposed on or otherwise be incurred by any Related Person under this Agreement or any documents
or instruments delivered in connection herewith for any claim based on, in respect of or by reason of such obligations or by their creation. The Related Persons shall be express third party beneficiaries of and may enforce this
Section 12. 
 (The remainder of this page is intentionally left blank.) 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date
first written above. 
  

			
	ENDURANCE SPECIALTY HOLDINGS LTD.
		
	By:	 	 /s/ John Del Col

	Name:	 	John Del Col
	Title:	 	General Counsel and Secretary

 
			
	CVC CAPITAL PARTNERS ADVISORY (US), INC.
		
	By:	 	 /s/ Kamil M. Salame

	Name:	 	Kamil M. Salame
	Title:	 	Partner, U.S. Head of Financial Institutions Group
	
	GIC SPECIAL INVESTMENTS PTE. LTD.
		
	By:	 	 /s/ Eric Wilmes

	Name:	 	Eric Wilmes
	Title:	 	Authorized Signatory
	
	Solely for purposes of Sections 3, 4, 6, 7, 8, 9, 10, 11 and 12:
	
	 CVC European Equity V Limited

as general partner of

CVC EUROPEAN EQUITY PARTNERS V (A) L.P.

		
	By:	 	 /s/ Carl John Hansen

	Name:	 	Carl John Hansen
	Title:	 	Director
	
	 CVC European Equity V Limited

as general partner of
 CVC EUROPEAN EQUITY PARTNERS V
(B) L.P.

		
	By:	 	 /s/ Carl John Hansen

	Name:	 	Carl John Hansen
	Title:	 	Director
	
	 CVC European Equity V Limited

as general partner of
 CVC EUROPEAN EQUITY PARTNERS V
(C) L.P.

		
	By:	 	 /s/ Carl John Hansen

	Name:	 	Carl John Hansen
	Title:	 	Director

 
			
	CVC European Equity V Limited
	as general partner of
	CVC EUROPEAN EQUITY PARTNERS V (D) L.P.
		
	By:	 	 /s/ Carl John Hansen

	Name:	 	Carl John Hansen
	Title:	 	Director
	
	 CVC European Equity V Limited

as general partner of

	CVC EUROPEAN EQUITY PARTNERS V (E) L.P.
		
	By:	 	 /s/ Carl John Hansen

	Name:	 	Carl John Hansen
	Title:	 	Director
	
	CLIFF INVESTMENT PTE. LTD.
		
	By:	 	 /s/ Eric Wilmes

	Name:	 	Eric Wilmes
	Title:	 	Authorized Signatory

 Exhibit A 

Term Sheet 

This Term Sheet sets forth the principal terms pursuant to which the Investment (as defined below) would be made. Capitalized terms used
but not defined herein have the meanings ascribed thereto in the Agreement of which this Exhibit A forms a part. 
  

			
	Issuer:	  	Endurance Specialty Holdings Ltd. (the “Company”)
		
	Investment:	  	$250 million (the “Investment”).
		
	Security:	  	Newly issued ordinary shares, par value $1.00 per share, of the Company (the “Ordinary Shares”).
		
	Listing:	  	NYSE
		
	Purchase Price Per Ordinary Share:	  	The purchase price per share of the Ordinary Shares shall be equal to $50.03, as adjusted for any stock splits, stock dividends or combinations prior to the closing of the Investment (the “Purchase Price Per Ordinary
Share”).
		
	Warrants:	  	 Upon the closing of the Investment, the Company will grant to the Equity Option Investors on a pro rata basis warrants (the
“Warrants”) to purchase Ordinary Shares equal to 38.5% of the number of Ordinary Shares acquired by the Equity Option Investors in connection with the Investment, at an exercise price equal to $58.86 per share, as adjusted for any
stock splits, stock dividends or combinations prior to the closing of the Investment.
  

The Warrants will have a term of 10 years from the closing date of the Investment. Any dividends (other than stock dividends) on the Ordinary Shares will
reduce the exercise price of the Warrants. The Warrants will have customary anti-dilution protection for share-splits, share combinations, share dividends and certain distributions to shareholders. In addition, the holder of Warrants will have the
right to exchange the Warrants for Ordinary Shares of equivalent value in a transaction intended to qualify as a recapitalization within the meaning of Section 368(a)(1)(E) as well as the right to exercise the Warrants by means of a customary
cashless exercise provision.
  
 The CVC Purchaser shall have the right to transfer up to
1.5% of the total Warrants (the “Warrant Transfer”) and each Equity Option Investor shall share a pro rata reduction in the number of Warrants received; provided that any such Warrant Transfer shall only be made to a person
or entity in consideration for providing insurance industry consulting services to an Equity Option Investor or its affiliates.

  
 A-1 

			
		  	  
 No Equity Option Investor or any of its affiliates is permitted to
compensate any of the Company’s financial advisors in any manner, including through a Warrant Transfer, in connection with the Transaction.
  

No Equity Option Investor or any of its affiliates is permitted to compensate any director of the Company or any its subsidiaries with respect to his or her
service on such board of directors or any committee thereof.
  

	Board Representation:	  	 Upon the closing of the Investment by the CVC Purchaser, the CVC Purchaser shall have the right to nominate one director (the “CVC
Nominated Director”) to the Board of Directors of the Company. In the event the CVC Nominated Director is any person other than Christopher Stadler or Kamil Salame, such CVC Nominated Director shall be subject to the approval of the
Company’s Board of Directors (such approval not to be unreasonably withheld) and shall, in all cases, qualify as an independent director for purposes of NYSE rules. The CVC Purchaser will not nominate any person who is, or formally was, a
director, officer, manager, partner or employee of an entity owned or controlled by a foreign government or instrumentality of a foreign government or any of its affiliates, and in the event that the CVC Nominated Director becomes a director,
officer, manager, partner or employee of an entity owned or controlled by a foreign government or instrumentality of a foreign government or any of its affiliates, the CVC Purchaser shall cause the CVC Nominated Director to forthwith resign from the
Board of Directors of the Company, and shall nominate a CVC Nominated Director to replace such resigning CVC Nominated Director who satisfies the requirements set forth in the first part of this sentence.

 
 The CVC Purchaser will continue to have the right to nominate one director so long as the
CVC Purchaser owns at least $100 million of the Ordinary Shares purchased pursuant to the Investment (based on the Purchase Price Per Ordinary Share) (excluding any Ordinary Shares issued and outstanding in connection with the CVC Purchaser’s
exercise of the Warrants).
  
 For so long as the CVC Purchaser owns at least the
requisite amount of Ordinary Shares as set forth above, the Nominating and Corporate Governance Committee of the Company’s Board of Directors will submit one CVC Nominated Director to be nominated at an annual general meeting of the Company
shareholders.1

  

	1 	In the event of a casual vacancy on the Company’s Board of Directors (e.g., in the event the CVC Nominated Director is not re-elected or a newly proposed designee of the CVC Purchaser is not elected, as the case
may be, resulting in a vacancy on the Board), the then remaining directors will appoint another director designated by the CVC Purchaser as such director’s successor for the term applicable to such non-reelected CVC Nominated Director or
non-elected proposed designee, as the case may be. For clarity, a new designee of the CVC Purchaser will be nominated by the CVC Purchaser to the Board as a replacement in respect of any CVC Nominated Director not being re-elected or a newly
proposed designee of the CVC Purchaser not being elected (i.e., cannot simply re-nominate a director who was not approved by the Company’s shareholders to any such casual vacancy). 

  
 A-2 

			
		  	  
 Any CVC Nominated Director will be entitled to enter into an
indemnification agreement on the same terms as those entered into by other directors of the Company.

		
	Preemptive Rights:	  	For so long as the Equity Option Investors own at least $100 million of the Ordinary Shares purchased pursuant to the Investment (based on the Purchase Price Per Ordinary Share) (excluding any Ordinary Shares issued and outstanding
in connection with the Equity Option Investors’ exercise of the Warrants), each Equity Option Investor will be entitled to purchase its then current pro rata portion (as represented by Ordinary Shares, excluding any Ordinary Shares issued and
outstanding in connection with such Equity Option Investor’s exercise of the Warrants) of any future issuances by the Company of its Ordinary Shares or securities convertible into, or exchangeable or exercisable for, Ordinary Shares on the same
terms as such Ordinary Shares or such other securities are being issued, other than (i) pursuant to the granting or exercise of employee share options, RSUs or restricted shares pursuant to the Company’s equity-based incentive plans, (ii) an
issuance of Ordinary Shares under the Company’s employee share purchase plan, (iii) pursuant to a refinancing of the Company’s Preferred Shares outstanding immediately after the closing of an Acquisition Transaction with convertible
Preferred Shares with a conversion price per Ordinary Share or Ordinary Shares with an issue price per Ordinary Share lower than the Purchase Price Per Ordinary Share (as equitably adjusted for any reclassification, stock split (including reverse
stock split), subdivision, combination, exchange or readjustment of Ordinary Shares on or after the Acquisition Transaction Closing Date, or any stock dividend or distribution with a record date on or after the Acquisition Transaction Closing Date),
(iv) any issuance of any equity securities (or securities convertible into, or exchangeable or exercisable for, equity securities) in connection with the replacement or refinancing of any debt incurred by the Company used to fund the cash portion of
the consideration to be paid in connection with an Acquisition Transaction and (v) such other exemptions as may be mutually agreed to by the Company and the Equity Option Investors.

  
 A-3 

			
		
	Access to Management and Information Rights:	  	For so long as the Equity Option Investors own at least $100 million of the Ordinary Shares purchased pursuant to the Investment (based on the Purchase Price Per Ordinary Share) (excluding any Ordinary Shares issued and outstanding
in connection with the Equity Option Investors’ exercise of the Warrants), the Equity Option Investors shall be entitled to access to management and information rights customary for investments of this type, subject to appropriate
confidentiality restrictions.
		
	Conditions to Closing:	  	Expiration or early termination of the waiting period under the HSR Act; no injunction; and listing of the Ordinary Shares on the NYSE.
		
	Lock-Up:	  	 No Equity Option Investor shall transfer any Ordinary Shares acquired by it in connection with the Investment (including any Ordinary Shares
acquired upon the exercise of the Warrants) to any Person (as defined below), other than to a Permitted Transferee (as defined below) thereof prior to 12 months following the closing of the Investment except (i) in connection with a tender offer for
the Ordinary Shares approved by the Board of Directors of the Company or (ii) to the Company pursuant to an authorized share repurchase program, in each case on a pro rata basis (as represented by Ordinary Shares, including any Ordinary Shares
issued and outstanding in connection with the Equity Option Investors’ exercise of the Warrants). With respect to clause (ii) of the preceding sentence, the Company and the Equity Option Investors will work together in good faith to agree upon
the timing, pricing and mechanics for undertaking any such share repurchase from the Equity Option Investors.
  

The 12 month lock-up period set forth in previous paragraph shall automatically terminate in the event the Company takes any of the following actions without
the prior written approval of the CVC Purchaser: (1) any merger or consolidation with another company or material investment in another company, in either case having a value of greater than 20% of the tangible book value of the Company; (2) any
acquisition or disposition of assets greater than 20% of the tangible book value of the Company; (3) any voluntarily initiated liquidation; (4) amend the Company’s organizational documents in a manner that would materially adversely and
disproportionately affect the Equity Option Investors compared to the other shareholders; (5) change the tax domicile of the Company; or (6) remove the Chief Executive Officer of the Company, other than for Cause (as such term is defined in the
Chief Executive Officer’s employment agreement).
  
 No Equity Option Investor shall
transfer any Warrant to any Person, other than to a Permitted Transferee thereof or pursuant to a Warrant Transfer, prior to 12 months following the closing of the Investment.

  
 A-4 

			
		
		  	 “Permitted Transferee” means: (i) any Affiliate (as defined below) of the applicable Equity Option Investor, so long as such
Person remains an Affiliate thereof (upon such Person ceasing to be an Affiliate thereof, the Ordinary Shares or Warrants, as applicable, are required to be transferred back to the applicable Equity Option Investor; (ii) any general or limited
partner or member of the applicable Equity Option Investor and any corporation, partnership or other entity that is an Affiliate of such general or limited partner or member, so long as such Person remains an Affiliate thereof (upon such Person
ceasing to be an Affiliate thereof, the Ordinary Shares or Warrants, as applicable, are required to be transferred back to the applicable Equity Option Investor); (iii) any managing director, general partner, director, limited partner, member or
officer of the applicable Equity Option Investor, or any spouse, lineal descendant, sibling, parent, heir, beneficiary under a will or similar instrument, executor, administrator, testamentary trustee, legatee or beneficiary of any of the foregoing
natural Persons described in this clause (iii), or (iv) any trust the beneficiaries of which, or any corporation, limited liability company or partnership the shareholders, members or general or limited partners of which, include only the applicable
Equity Option Investor or any Persons described in clauses (ii) or (iii), their spouses or their lineal descendants.
  

“Affiliate” means with respect to any Person, a Person that directly or indirectly controls, is controlled by or is under common control with
such Person; provided that for purposes of this definition, (a) “control” means (i) the power to direct the management and policies of a Person, directly or indirectly, through the ownership of voting securities or by binding
contract, (ii) ownership of at least a majority of the voting power of such Person and (iii) the ability to appoint or elect at least a majority of the board of directors or other governing body of such Person at all times; the terms
“controlled” and “controlling” have meanings correlative to the foregoing and (b) “common control” means that the same Person owns, directly or indirectly, at least 80% of the economic and voting interests in such
Person and such Affiliate; provided that the foregoing percentage limitation will not restrict inter-fund transfers otherwise meeting the requirements of clause (a) above).

 
 “Person” means an individual, partnership, corporation, limited liability
company, joint venture, joint stock company, trust, unincorporated organization, government (or an agency or political subdivision thereof) or other entity.
  

Prior to any transfer of Ordinary Shares or Warrants to a Permitted Transferee, such Permitted Transferee shall agree to be bound by the terms
herein.

  
 A-5 

			
		
	Investor Standstill:	  	Neither the Equity Option Investors nor any of their respective affiliates or Representatives (in the case of any Representative, so long as such Person is acting for or on behalf of the foregoing Persons) will, during the period
following the closing of the Investment until the later of (a) the five year anniversary of the closing of the Investment or (b) the Equity Option Investors beneficially owning less than 15% in the aggregate of the ownership of the Company acquired
by them in connection with the Investment (as represented by Ordinary Shares, including any Ordinary Shares issued and outstanding in connection with the Equity Option Investors’ exercise of the Warrants), without the consent of a majority of
the Company’s Board of Directors (exclusive of the CVC Nominated Director), assist, advise, act in concert or participate with or encourage others to, directly or indirectly: (i) acquire (or agree, offer, seek or propose to acquire, in each
case, publicly or privately), by purchase, tender offer, exchange offer, agreement or business combination or in any other manner, any ownership, including, but not limited to, beneficial ownership, as defined in Rule 13d-3 under the Exchange Act,
of, or economic exposure to, any of the assets, liabilities, businesses or securities of the Company or any direct or indirect subsidiary thereof, or any rights or options (including through any economic, hedging or “short sale”
transactions) to acquire such ownership or economic exposure (including from any third party) (provided, however, that this clause (i) shall not prohibit any acquisition of (A) securities of the Company or any direct or indirect
subsidiary thereof made in the ordinary course of any Equity Option Investor’s portfolio investment operations, which shall in no case include acquisitions in the aggregate by such Equity Option Investor (together with its affiliates) in excess
of 4.99% of the outstanding amount of any class of securities of the Company or any direct or indirect subsidiary thereof (provided that from and after the date of the Investment, the investor identified on Schedule I to the Agreement
of which this Exhibit A forms a part and its affiliates (including its public operations and its investment operations) will not own in excess of 9.9% of the Ordinary Shares on an aggregate basis), (B) Ordinary Shares through the exercise of the
Warrants or (C) Ordinary Shares by the CVC Purchaser from the investor identified on Schedule I to the Agreement of which this Exhibit A forms a part or its affiliates, including any Ordinary Shares issued and outstanding in connection with
such Equity Option Investor’s or its affiliates’ exercise of any Warrants; (ii) publicly (or privately, except to the extent public disclosure by the Company or the Equity Option Investors would not be required as reasonably determined by
the Company) offer to enter into, or publicly (or privately, except to the extent public disclosure by the Company or the Equity Option Investors would not be required as reasonably determined by the Company) propose, any merger,
business

  
 A-6 

			
		  	 combination, recapitalization, restructuring or other extraordinary transaction with the Company or any direct or indirect subsidiary
thereof; (iii) initiate any shareholder proposal or the convening of a shareholders’ meeting of or involving the Company or any direct or indirect subsidiary thereof; (iv) solicit proxies (as such terms are defined in Rule 14a-1 under the
Exchange Act), whether or not such solicitation is exempt pursuant to Rule 14a-2 under the Exchange Act, with respect to any matter from, or otherwise seek to influence, advise or direct the vote of, holders of any shares of capital stock of the
Company or any securities convertible into, exchangeable for or exercisable for (in each case, whether currently or upon the occurrence of any contingency) such capital stock, or make any communication exempted from the definition of solicitation by
Rule 14a-1(l)(2)(iv) under the Exchange Act); (v) otherwise seek or propose to influence, advise, change or control the management, board of directors (including proposing any director nominees), governing instruments, affairs or policies of the
Company or any direct or indirect subsidiary thereof, other than through exercise of the rights of the Equity Option Investors contemplated hereby; (vi) enter into any discussions, negotiations, agreements, arrangements or understandings with any
other Person (other than the Equity Option Investors or any of their respective affiliates subject to compliance with the foregoing clauses (i) through (vi)) with respect to any matter described in the foregoing clauses (i) through (vi) or form,
join or participate in a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) to vote, acquire or dispose of any securities of the Company or any of its subsidiaries; (vii) request a waiver, grant any consent under or
otherwise not enforce any provision of this paragraph of the Investor Standstill, except during the period the Company’s Board of Directors has publicly announced (and not publicly withdrawn) that the Company is evaluating strategic
alternatives and the Company is in fact soliciting acquisition proposals or (viii) make any public disclosure, or take any action that could reasonably be expected to require the Equity Option Investors or the Company to make a public disclosure,
with respect to any of the matters set forth in this paragraph of the Investor Standstill, other than any public disclosure by the Equity Option Investors or any of their respective affiliates which is required by judicial or governmental order,
discovery request, subpoena or similar compelled process (other than any such process commenced by the Equity Option Investors or their respective affiliates).
  

The foregoing provisions shall in no way limit the ability of the CVC Nominated Director to take actions (or to refrain from taking actions) in his or her
capacity as a director of the Company or for the Equity Option Investors to exercise their other rights contemplated hereby, and shall not limit the ordinary course activities of the
investor

  
 A-7 

			
		  	identified on Schedule I to the Agreement of which this Exhibit A forms a part or CVC Credit Partners Holdings Limited and its subsidiaries (including, without limitation, brokerage, investment, financial, merger or other
advisory, financing, asset management, trading, market making, arbitrage, and investment activities conducted in the ordinary course of business), if such activities are conducted in compliance with standard practices and procedures (including those
known as “Chinese Walls”) restricting the flow of information between personnel of the Equity Option Investors who have access to material non-public information of the Company and personnel of affiliates of the investor identified on
Schedule I to the Agreement of which this Exhibit A forms a part or CVC Credit Partners Holdings Limited.
		
	Board Fees:	  	The Company shall pay the CVC Nominated Director annual compensation, including director fees, equity compensation, and expenses equivalent to those paid to the Company’s other outside directors.
		
	Representations and Warranties:	  	The Company will make customary representations and warranties to the Equity Option Investors for an equity investment of the size contemplated hereby.
		  	

 *    *    *    *    * 

  
 A-8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]